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8ABSTRACT
Background
Type 1 diabetes is associated with the risk for late diabetic complications which 
are divided into microvascular (retinopathy, nephropathy, and neuropathy) 
and macrovascular (cardiovascular disease, CVD) diseases. The risk for diabetic 
complication can be reduced by effective treatment, most importantly the glycaemic 
control. Glycaemia in type 1 diabetes is infl uenced by the interplay between insulin 
injections and lifestyle factors such as physical activity and diet. The effect of physical 
activity in patients with type 1 diabetes is not well known, however. 
Aim
The aim of this thesis was to investigate the physical activity and the physical fi tness 
of patients with type 1 diabetes with special emphasis on glycaemic control and the 
diabetic complications. 
Subjects and methods
The patients included in the study were all part of the nationwide, multicenter 
Finnish Diabetic Nephropathy (FinnDiane) Study which aims to characterise 
genetic, clinical, and environmental factors that predispose to diabetic complications 
in patients with type 1 diabetes. In addition, subjects from the IDentifi cation of 
EArly mechanisms in the pathogenesis of diabetic Late complications (IDEAL) 
Study were studied. Physical activity was assessed in the FinnDiane Study in 1945 
patients by a validated questionnaire. Physical fi tness was measured in the IDEAL 
Study by spiroergometry in 86 young adults with type 1 diabetes and in 27 healthy 
controls. All patients underwent thorough clinical characterisation of their diabetic 
complication status. Four substudies were cross-sectional using baseline data and 
one study additionally used follow-up data.                
Results           
Physical activity, especially the intensity of activities, was reduced in patients affected 
by diabetic nephropathy, retinopathy, and CVD. Low physical activity was associated 
with poor glycaemic control, a fi nding most clear in women and evident also in 
patients with no signs of diabetic complications. A higher level of physical activity 
was also associated with better insulin sensitivity. Furthermore, low physical activity 
was associated with a higher HbA
1c
 variability, which in turn was associated with 
the progression of renal disease and CVD during follow-up. The prevalence of the 
metabolic syndrome in type 1 diabetes was also lower the higher the physical activity. 
The aerobic physical fi tness level of young adults with type 1 diabetes was reduced 
9compared with healthy peers and in men an association between higher fi tness 
level and lower HbA
1c
 was observed.
Conclusions
In patients with type 1 diabetes, a higher physical activity was associated with better 
glycaemic control and may thus be benefi cial with respect to the prevention of 
diabetic complications. 
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1. INTRODUCTION
Diabetes, defi ned as elevated blood glucose concentrations, is a major health problem 
in today’s society as the number of patients with diabetes is growing continuously. 
Globally, the number of adult patients with diabetes is 285 million (6.6% of the 
population) according to the 2009 fi gures of the International Diabetes Federation, 
and is thought to increase to 435 million (7.8%) by the year 2030 1. In Finland, it 
is estimated that the current number of patients with diabetes is close to 300 000 
individuals, and another 200 000 is estimated to have yet undiagnosed diabetes. 
Hence half a million, or close to 10% of the total Finnish population, is thought to be 
affected by diabetes. Of these, 40 000 patients have type 1 diabetes, and the majority 
of the remaining patients have type 2 diabetes. The hallmarks of type 1 diabetes 
are onset at younger age and an unconditional dependence on insulin treatment 
for survival due to the cessation of the insulin production of the pancreas. Type 2 
diabetes is usually characterised by a later age at onset and the patients are usually 
not dependent on insulin treatment for survival. Even though the patients with 
type 1 diabetes represent a minority of all patients with diabetes, the proportion of 
patients with type 1 diabetes is exceptionally high in Finland, and in fact Finland 
has the highest incidence of type 1 diabetes in the world 2. The incidence of type 1 
diabetes has clearly increased in Finland during the last decades 3 for reasons that 
are not fully understood. This thesis will focus on type 1 diabetes.
Before the discovery of insulin by Frederick Banting and Charles Best during 1921-
1922 in Canada at the University of Toronto; type 1 diabetes was a fatal illness and the 
patients died from dehydration and disturbances in their acid-base- and electrolyte 
balance. This acute condition, referred to as diabetic ketoacidosis, is caused by 
a failure of the endogenous insulin production and subsequent hyperglycaemia 
and increased lipid oxidation followed by high ketone body formation. This life-
threatening condition can nowadays be successfully treated with exogenous insulin 
and replacement of fl uid and electrolytes and the disease can be kept under control 
by subcutaneous injection of insulin. Such treatment has been available since 1922, 
when insulin was for the fi rst time successfully administered to a patient with 
diabetes. 
However, type 1 diabetes was not a fully solved problem, because it soon became 
obvious that the patients, despite their insulin treatment, developed a uniform array 
of symptoms and illnesses such as impaired renal function, decreased vision and 
blindness, decreased skin sensation and ulcers in the lower extremities, heart disease 
and, importantly, a clearly decreased lifespan. These diabetes-related illnesses have 
been recognised as diabetic kidney disease (nephropathy), eye disease (retinopathy), 
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and nerve disease (neuropathy) and collectively constitute the classical microvascular 
complications of diabetes. In addition, macrovascular complications manifest as 
atherosclerotic lesions in the coronary and the peripheral arteries, for instance in the 
lower extremities and the brain. The diabetic complications probably arise because 
the exogenous delivery of insulin does not adequately restore the physiologic effects 
of a properly functioning endogenous insulin secretion. 
Even though the insulin treatment has undergone much improvement since 
1922, the diabetic complications continue to be a major problem for patients with 
type 1 diabetes. Even today, diabetic complications confer a reduced quality of 
life and a shortened lifespan. In addition, the treatment of diabetic complications 
is expensive for the society and 9.2% (1.35 billion euro) of the total health care 
budget of Finland was used for the treatment of diabetes and its complications 4 in 
2007, and similar relative expenses have been reported from the USA 5. Diabetic 
nephropathy can be considered the most severe diabetic complication, because 
diabetic nephropathy is strongly associated with an increased risk of end-stage renal 
disease with subsequent need of dialysis and renal transplantation for survival, and 
also with increased risk of cardiovascular disease 6 and premature death 7, 8. The 
presence or absence of albumin in the urine is a major determinant of the prognosis 
of patients with type 1 diabetes, and recent data suggest that patients with normal 
urinary albumin excretion rate (<30 mg/24h) in fact have a standardised mortality 
rate that is no different from that of the general population 8.  
Hyperglycaemia is a prerequisite for the development of diabetic complications, 
but is not a sole causative factor. Hypertension and blood lipids are also known to 
be important players in the cascade leading to diabetic complications. More recently 
endothelial dysfunction, low-grade infl ammation, oxidative stress, and insulin 
resistance have also been implicated in the pathogenesis. Accordingly, interventions 
aimed to reduce the development and progression of diabetic complications should 
target multiple factors. 
Physical activity is known to have many health benefi ts and has been implicated 
as part of the treatment and prevention of a vast number of diseases 9. From studies 
in patients with type 2 diabetes we know that physical activity improves the glycaemic 
control 10, but in type 1 diabetes the true effect on glycaemic control is still an open 
question, even though a positive effect has been demonstrated on insulin sensitivity 
11-13. Physical activity may also reduce the blood pressure 14, improve the blood lipid 
profi le 15, 16, and may have positive effects on the endothelial function 17, 18. Therefore, 
physical activity could be an effective means to prevent diabetic complications 
through multiple mechanisms. If proven effective, more fi nancial resources need 
to be directed towards the enhancement of physical activity of patients with type 
1 diabetes. There is undoubtedly a need for data on the effect of physical activity 
on health outcomes in these patients, because there are only a small number of 
12
available studies with low numbers of patients. The main aim of this thesis was to 
examine the relationship between physical activity and glycaemic control in a large 
set of patients with type 1 diabetes.
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2. REVIEW OF THE LITERATURE
2.1 DIABETES MELLITUS
Diabetes mellitus, henceforth referred to as diabetes, is a group of metabolic 
conditions characterised by elevated blood glucose concentrations. According to 
the World Health Organisation (WHO), diabetes is currently defi ned as a fasting 
plasma glucose concentration of ≥7.0 mmol/l in repeated measurements, or a 2 
h oral post-glucose load (75g) plasma glucose concentration of ≥11.1 mmol/l 19. 
Additionally, a random plasma glucose value of ≥11.1 mmol/l in conjunction with 
symptoms of diabetes (thirst, polyuria, weight loss) also leads to a diagnosis of 
diabetes. The fasting glucose value for diabetes has been lowered several times 
during the past 30 years. The 1980 WHO criterion of ≥8.0 mmol/l 20 was lowered 
fi rst in 1985 to ≥7.8 mmol/l 21 and again in 1999 to the current defi nition of ≥7.0 
mmol/l 22. A HbA
1c
-based (see section 2.1.3) defi nition of diabetes, however, is 
currently a matter of debate 23.
Historically, the word diabetes comes from the Greek word “diabainein”, which 
means “to pass through” and refers to the large urine volume that is associated 
with diabetes. Mellitus comes from the Latin word “mel” which means honey, and 
refers to the sweetness of urine. As a disease, diabetes was known already in Egypt 
about 3500 years ago. In the fi rst century AD, Aretaeus of Cappadocia described 
the condition as the “melting down of the fl esh and limbs into urine”; a horrifi c but 
accurate description of untreated diabetes. Diagnosis in the early days was based 
on the sweetness of the urine, and involved either tasting of the urine by the doctor 
or evaluating the degree of attraction of ants to the urine specimen.
Diabetes is not a single disease, but rather a group of diseases with different 
pathophysiological mechanisms that result in elevated plasma glucose concentrations. 
The underlying problem is a disturbed effect of insulin, which is secreted from the 
β-cells of the islets of Langerhans in the pancreas. This disturbance may be due 
either to a decreased production or to a decreased effect (or both) of insulin in the 
target tissues, which are the skeletal muscles, the adipose tissue, and the liver. In 
addition to disturbances in the glucose metabolism, a defective insulin action also 
leads to disturbances in the lipid and the amino acid metabolism.
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2.1.1 CLASSIFICATION OF DIABETES
There are two main types of diabetes, which are called type 1 and type 2 diabetes 
according to the current terminology set by the National Diabetes Data Group in 
1979 24 and the WHO in 1980 20. Type 1 diabetes, or insulin-dependent diabetes, is 
the clinical manifestation of the abovementioned ancient descriptions of diabetes, 
and is due to a failure of the pancreas to produce insulin. Type 2 diabetes, or 
non-insulin-dependent diabetes, is closely related to obesity and decreased insulin 
sensitivity, but accumulating data indicate that also insulin secretion defects are 
fundamental in the pathogenesis of type 2 diabetes. Most susceptibility genes for type 
2 diabetes known at the moment, for instance the TCF7L2 25, are in fact involved in 
the regulation of insulin secretion, not insulin sensitivity. The distinction between 
type 1 and type 2 diabetes is often anything but clear, and in the clinical setting 
there is a considerable overlap between these two conditions. Patients with “double 
diabetes” 26 have also been reported, which refers to features of type 2 diabetes, 
such as obesity and insulin resistance, in patients diagnosed with type 1 diabetes. 
In line with this, Finnish patients with type 1 diabetes frequently fulfi l the criteria 
for the metabolic syndrome 27. 
There are also other forms of diabetes, which constitute a minority of patients 
with diabetes. Latent autoimmune diabetes in adults (LADA) falls between type 1 
and type 2 diabetes because it involves autoimmune destruction of the β-cells of 
the pancreas, however at an older age than that of classical type 1 diabetes and the 
patients are usually not insulin-dependent at the time of diagnosis 28. Another part 
of the spectrum of diabetes is maturity-onset diabetes of the young (MODY), which 
is characterised by lower age at onset than in type 2 diabetes, but absence of both 
ketoacidosis and β-cell autoimmunity typical for type 1 diabetes 29. MODY differs 
from the other forms of diabetes by an autosomal dominant inheritance with high 
penetrance. The primary causal defects have been identifi ed at the molecular level 
for the subtypes MODY 1 to 6. For instance, the most common form in Finland is 
MODY-3 which is caused by a mutation in the hepatocyte nuclear factor 1α 30 causing 
defects in the insulin secretion but is still associated with normal insulin sensitivity 
31. There is also a heterogeneous group of secondary forms of diabetes, which may be 
caused by pancreatitis, pancreatic cancer, surgery, or other trauma to the pancreas 
with subsequent insulin defi ciency. Long-term use of glucocorticoid medication 
can induce diabetes by reducing insulin sensitivity 32 and another iatrogenic form 
of diabetes is related to the use of cyclosporine treatment as immunosuppressant 
after organ transplantations 33. Finally, gestational diabetes refers to hyperglycaemia 
manifesting during pregnancy, which is a state of relative insulin resistance, and is 
a risk factor for future type 2 diabetes 34.
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2.1.2 TYPE 1 DIABETES
Type 1 diabetes is characterised by an autoimmune destruction in the β-cells of the 
pancreas and has in many cases an acute onset with ketoacidosis 35. Type 1 diabetes 
usually manifests before the age of 30 years, but can present at any age. 
2.1.2.1 Epidemiology
The incidence rates of type 1 diabetes show striking geographical differences. Data 
from the years 1990-1999 showed that the countries with the highest yearly incidence 
per 100 000 individuals aged <15 years were Finland (40.9), the Italian island of 
Sardinia (37.8), and Sweden (30.0) 36. The most recent numbers from Finland show 
that the incidence has risen even more rapidly than expected, now 64.2 new cases 
per 100 000 aged <15 years in 2008 2. These numbers are in sharp contrast to 
countries like Venezuela, Peru, and China where the incidence rate is <1 per 100 000 
36. Thus, the worldwide regional differences in the incidence of type 1 diabetes is 
more than 60-fold. These remarkable regional differences may also give some clues 
to the etiological factors of type 1 diabetes. The increase in the incidence during the 
last decades has been too large to be explained only by genetic factors, and thus 
strongly implies the involvement of environmental factors 37. The temporal aspect 
can also be informative as the sharp rise in incidence began in the mid 1950s in 
several populations (Finland, Norway, Denmark, Sardinia, and USA) in a seemingly 
synchronized fashion 38, 39, however with the caveat that early incidence estimates 
may be unreliable due to death of patients with undiagnosed diabetes. 
The age at onset of type 1 diabetes seems to be getting younger in many 
populations, especially the proportion diagnosed before fi ve years of age 40. According 
to the spring harvest theory 39, 41, the apparent increase in the incidence of type 1 
diabetes is attributable to a decrease in the age at onset of the disease. In support 
of this, the cumulative incidence of type 1 diabetes before the age of 39 years has 
been unchanged in Sweden 42 and in Belgium 43. 
Finland appears to be a hot-spot for type 1 diabetes. The increase in incidence 
continues in a linear 3 or even exponential 2 fashion, while a plateau is seen in other 
countries with already high incidence of type 1 diabetes 44. Moreover, the spring-
harvest theory does not fully explain the situation in Finland where an increase in 
the incidence is observed not only in young age groups (<15 years) 2, but also in the 
age group of 15-39 years 45, 46. The reason(s) for this exceptional situation in Finland 
is unknown, but if solved could lead to better understanding of the mechanisms 
behind type 1 diabetes.
16
2.1.2.2 Pathogenesis
Type 1 diabetes is caused by an autoimmune attack directed against the β-cells of 
the islets of Langerhans in the pancreas. The disease usually manifests when 80-
90% of the total β-cell population is lost 47. As a marker of autoimmunity, certain 
autoantibodies against islet antigens can be found in the serum before, at, and after 
the diagnosis of type 1 diabetes. These are glutamic acid decarboxylase (GAD), islet 
cell (IC), insulin (IA), and protein tyrosine phosphatase IA-2 antibodies. Autoreactive 
T-lymphocytes are also important in the destruction of pancreatic β-cells. The clinical 
course of type 1 diabetes varies from a fulminant, rapidly evolving disease 48 to one 
with a slower onset during several years. After the diagnosis has been made and the 
insulin treatment initiated, a “honey-moon period” that is due to a partial recovery 
of the β-cell function can be seen. The autoimmune attack, however, will ultimately 
lead to total dependence on exogenous insulin. 
The cascade leading to β-cell destruction by a misdirection of the body’s own 
defence mechanisms involves both genetic predisposition, environmental triggers, 
and modifying factors 49. All these factors act in concert in a cascade of differing 
order and timing of events that is probably unique for each patient who develops 
type 1 diabetes. 
Of the genetic predisposition, about half is thought to derive from the human 
leukocyte antigen (HLA) region on chromosome 6p21 50. Especially HLA DR3/
DR4 is enriched in patients with type 1 diabetes. Other (non-HLA) genes that have 
been convincingly associated with type 1 diabetes include the variable-number 
tandem repeat (VNTR) variant of the insulin gene 51, the cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) 52, and the protein tyrosine phosphatase-22 (PTPN22) 
53. Large-scale genome-wide association studies for type 1 diabetes have recently 
been performed 54, 55 discovering several previously unknown susceptibility genes, 
but there are certainly many more yet unknown genetic loci that confer risk. 
There are, however, several observations indicating that type 1 diabetes is not a 
purely genetic disease. First, the predisposing genes have a low penetrance, because 
most carriers of risk alleles do not develop type 1 diabetes and the concordance for 
type 1 diabetes in monozygotic twins is only 13-33% 56, 57. Second, the prominent 
increase in the incidence of type 1 diabetes during the last decades cannot be 
explained by genetic factors as the required changes in the gene pool cannot 
occur within such a short time. Third, the proportion of high-risk HLA genotypes 
in patients with newly diagnosed type 1 diabetes has decreased with time, and 
conversely the proportion of low-risk, and even protective, genotypes has increased, 
suggesting a stronger environmental contribution 37. Migration studies are scarce, 
but there is some support of increased risk of type 1 diabetes in those who have 
moved from a region of low to one of high incidence of type 1 diabetes 58. Finally, 
seasonal variation with higher incidence of type 1 diabetes during the winter months 
also points to an environmental impact 59.
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There have been a number of suggested environmental factors associated with 
the onset of type 1 diabetes. The prime suspects have been viral infections, such as 
Coxsackie A and B viruses 60. In this context, a puzzling fact is that there has been 
a declining trend of enterovirus infections alongside an increase in the incidence 
of type 1 diabetes in the developed countries. This observation may, however, be 
explained by a decreased transfer of maternal antibodies against enteroviruses to 
children, who will thus have a reduced protection. This phenomenon was called 
the “polio hypothesis” 61 as an analogy to the increase of paralytic poliomyelitis in 
parallel with the decrease in polio infections. Recently, the enterovirus hypothesis 
was strengthened by high occurrence of the enteroviral capsid protein in the pancreas 
of patients with recent-onset fatal diabetes 62. In Finland the seasonal variation in 
the appearance of type 1 diabetes autoantibodies shows a peak at the same time 
as the highest occurrence of enterovirus infections which is during the winter 49. 
Vitamin D defi ciency during the dark period of the year may be another explanation 
for the seasonal variation on the northern hemisphere 63. Dietary factors have also 
been implicated, such as cow’s milk 64, 65, a short period of breast feeding 66, and 
gluten 67. Interestingly, countries with high consumption of root vegetables have 
high incidence of type 1 diabetes, and the common potato scab disease is caused 
by strains of Streptomyces-bacteria which produce toxins that are harmful for the 
β-cells 68. Streptozotocin is such a toxin which, in fact, is widely used for experimental 
induction of insulin-dependent diabetes in animal models. 
The growing obesity problem is another aspect of the rising incidence and 
younger age at onset of type 1 diabetes. The “accelerator hypothesis” states that 
factors that decrease insulin sensitivity stress the ß-cells of the pancreas, especially if 
they are already weakened by autoimmunity, leading to an accelerated pathogenesis 
of type 1 diabetes 69. Obesity and insulin resistance have traditionally been considered 
crucial in the pathogenesis of type 2 diabetes, but also seem to play a role as a 
modifying factor in the chain of events leading to type 1 diabetes 70, 71. Even though an 
increase in childhood obesity and insulin resistance may explain the spring harvest 
phenomenon mentioned in section 2.1.2.1 it is not likely to explain the absolute 
increase in incidence of type 1 diabetes. It is noteworthy that the clear distinction 
between type 1 and type 2 diabetes seems to fade away, and it has been proposed 
that type 1 and type 2 diabetes are in fact one and the same disease, but that the 
crucial difference is merely the rate of β-cell loss 69.
2.1.2.3 Treatment
Patients with type 1 diabetes are treated with exogenous insulin which is available 
as long- and short-acting preparations to cover the basal and postprandial need of 
insulin, respectively. Insulin is delivered subcutaneously, either as injected boluses or 
18
as a continuous infusion by an insulin pump. The insulin treatment regimen should 
be fl exible and insulin dose adjustments according to diet and physical activity, 
but also other factors such as infections are important. Islet cell transplantation 
as a potential cure for type 1 diabetes and with the aim to restore β-cell function 
is under development 72. Pancreas transplantation has also been performed in 
combination with renal transplantation in patients with renal failure 73. Another 
approach is to initiate immunosuppressive treatment and perform autologous stem-
cell transplantation in newly-onset type 1 diabetes 74, but there is an ethical dilemma 
due to long-term safety concerns. GAD-treatment in recent-onset type 1 diabetes 
was further shown to preserve residual insulin secretion, but long-term treatment 
effects are uncertain 75.
2.1.3 GLYCAEMIC CONTROL IN DIABETES
The long-term glycaemic control of patients with diabetes is clinically determined 
by the HbA
1c 
test, which is a measure of the proportion of haemoglobin molecules 
with glycosylation of the N-terminal valine residue of the haemoglobin β-chain. 
HbA
1c
 is usually expressed as % but more recently as mmol/mol. In this thesis, 
HbA
1c 
is given as %. Glycaemic control in diabetes has been estimated by HbA
1c
 
since the late 1970´s 76. HbA
1c 
is generated by non-enzymatic glycosylation at a rate 
proportional to the blood glucose concentration. The lifespan of the haemoglobin-
containing red blood cells is about 120 days; thus the HbA
1c 
value refl ects the average 
glycaemic control of the past three months of a patients with diabetes. The past 
month, however, may have a relatively larger impact on the HbA
1c 
value 77. There 
is some evidence that also hereditary factors affect the HbA
1c 
level in patients with 
type 1 diabetes 78. 
2.2 DIABETIC COMPLICATIONS
The diabetic complications are divided into microvascular (nephropathy, retinopathy, 
and neuropathy) and macrovascular (cardiovascular) disease. Once considered a 
part of type 1 diabetes itself, the observation that similar complications also arise 
in patients with secondary diabetes led to the view that complications are caused 
by the hyperglycaemic milieu. The blood glucose values that defi ne diabetes itself 
are set by the risk of diabetic microvascular complications 19.
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2.2.1 DIABETIC NEPHROPATHY
In the year 1936 eight adults, of which seven had known diabetes, were described 
as having similar fi ndings of high blood pressure, oedema, and proteinuria. Post-
mortem histological evaluation of their kidneys revealed that the patients had lesions 
of glomerulosclerosis 79. This condition, occasionally referred to as the Kimmelstiel-
Wilson syndrome, is the fi rst description in the literature of diabetic renal disease, 
or diabetic nephropathy. Besides glomerulosclerosis, the histological picture of 
diabetic nephropathy involves thickening of the glomerular basement membrane, 
and mesangial matrix expansion 80.
2.2.1.1 Defi nitions
Diabetic nephropathy, or diabetic kidney disease, is defi ned based on the urinary 
albumin excretion rate (UAER) determined by a timed urine collection. Another 
method suitable for screening is a spot urine sample from which the albumin-to-
creatinine ratio (ACR) is measured. Normal values for UAER are <30 mg/24h or 
<20 μg/min (in an overnight collection), also referred to as normoalbuminuria. 
Diabetic nephropathy, or macroalbuminuria, is diagnosed when the UAER is ≥300 
mg/24h or ≥200 μg/min, which is the level of dipstick-positive albuminuria, in 
two out of three consecutive urine collections. The intermediate range of UAER, or 
≥30 but <300 mg/24h or ≥20 but <200 μg/min is called microalbuminuria, and 
is regarded as a risk factor for overt nephropathy. End-stage renal disease (ESRD) 
refers to renal failure requiring dialysis treatment or kidney transplantation for 
survival. The arbitrary cut-off values of the UAER represent clinical consensus, and 
it has to be recognised that the degree of risk related to renal involvement in type 1 
diabetes probably spans the whole range of UAER. Albuminuria is a marker of renal 
injury, but has also been implicated in the pathogenesis of diabetic nephropathy 81. 
In itself UAER does not determine the level of renal function, which also is needed 
to fully assess the degree of renal involvement in patient with diabetes. 
2.2.1.2 Renal function
Renal function, usually expressed as the glomerular fi ltration rate (GFR), can be 
measured or estimated in several ways. The golden standard is the chromium EDTA 
method (Cr51-EDTA) 82 which, however, is a laborious method that is mostly used 
for research purposes. Clinically, the measurement of serum creatinine is the most 
frequently used method. Creatinine is a waste turnover product of skeletal muscle 
creatine (see section 2.4.1.1) which is freely fi ltered and secreted by the kidneys. 
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Creatinine has, however, limitations due to an active tubular secretion which 
counteracts a rise in serum creatinine at early stages of decreased renal function. 
A rise in serum creatinine is therefore a rather late manifestation of renal disease. 
Muscle mass may additionally infl uence the creatinine production. A relatively new 
serum marker of renal function is cystatin C 83 which is produced at a constant 
rate and is freely fi ltered in the kidneys without active tubular secretion and might 
therefore be a better serum marker of renal function than creatinine 84. GFR can 
also be estimated by measuring the creatinine clearance in a 24h urine collection 
but due to the active tubular secretion, the creatinine clearance will be higher than 
the actual GFR. Cystatin C clearance cannot be determined because cystatin C is 
mostly degraded by the tubular epithelial cells and is not secreted into the urine.   
GFR is clinically most often estimated from serum creatinine by formula 
calculations correcting for body mass, age, sex, and ethnicity which improve 
accuracy. The most commonly used are the Cockcroft-Gault 85 and the Modifi cation 
of Diet in Renal Disease (MDRD) 86 formulas. The Cockcroft-Gault formula was 
developed based on creatinine clearance, and thus does not strictly speaking calculate 
GFR. The Cockcroft-Gault formula was derived from a population of men with a 
wide range of creatinine clearance, while the MDRD formula was derived from 
patients with chronic kidney disease. These formulas have limitations especially in 
populations without established chronic kidney disease 87. The recently developed 
CKD-EPI formula performed better than the MDRD at normal GFR values 88. GFR 
is usually adjusted for body-surface area, and expressed as ml per minute per 1.73 
m2. Reference values for GFR are as follows: normal: >90, mildly reduced: 60-89, 
moderately reduced: 30-59, severely reduced: 15-29, and kidney failure <15 ml/
min/1.73 m2. 
2.2.1.3 Epidemiology
Diabetic nephropathy is becoming a major problem as the incidence of diabetes 
is increasing. Diabetes is currently the most common cause of renal failure in the 
Western World 89, 90. In patients with type 1 diabetes, the classical view is that 
about one patient out of three develops kidney disease 7, 91. There is, however, data 
indicating a decline in the incidence of diabetic nephropathy over time in some 92, 93, 
but not all 94 studies. The early studies which established microalbuminuria as the 
most important early marker for diabetic nephropathy in type 1 diabetes indicated 
that up to 80% of patients with microalbuminuria progress to macroalbuminuria, or 
overt nephropathy, over 6-14 years 95-97. These studies used inconsistent defi nitions 
of microalbuminuria, and later a joint effort 98 unifi ed the cut-off level to that of 
today (see section 2.2.1.1). More recent reports indicate that the fate of patients 
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with type 1 diabetes and microalbuminuria is not as grim as initially thought. In 
patients with a diabetes duration >15 years, 28% of patients with microalbuminuria 
progressed to macroalbuminuria during 10 years 99. In addition, regression of micro- 
to normoalbuminuria is common, in up to 58% of patients with microalbuminuria 
100. Of special value is a report from a Danish inception cohort of 286 consecutive 
patients with newly diagnosed type 1 diabetes who were followed for 18 years 101. 
This study showed a cumulative incidence of persistent microalbuminuria of 33.6% 
and macroalbuminuria of 14.6%, and 35.4% of the patients with microalbuminuria 
regressed back to normoalbuminuria. Therefore, the impact of microalbuminuria 
in the prediction of diabetic nephropathy in patients with type 1 diabetes is not 
as large as initially reported, but is still the best early non-invasive predictor in 
clinical use 102. 
2.2.1.4 Risk factors 
The pathways leading to diabetic nephropathy are thought to involve both genetic 
and environmental factors intertwined in a complex fashion. Fundamental risk 
factors for diabetic nephropathy are: glycaemic control 103, blood pressure 104, 105, male 
gender 91, 106, smoking 107, and ethnicity (blacks having higher risk than Caucasians) 
108, 109. 
Glycaemic control is important for the development of diabetic nephropathy. 
This fact was established by the landmark Diabetes Control and Complications Trial 
(DCCT) which showed a 54% reduction in the incidence of diabetic nephropathy in 
patients with type 1 diabetes by lowering of the HbA
1c
 by 2%-units 103. Previously the 
Steno 110, the Oslo 111, and the Stockholm 112 studies had also shown reductions in renal 
outcomes by lowering of the HbA
1c
. In addition to the mean level of glycaemia, it 
has been discussed that glycaemic variability might confer additional risk of diabetic 
complications 113. The thought is that hyperglycaemic peaks may have detrimental 
cellular effects 114-117 which ultimately might cause kidney damage. In patients with 
type 2 diabetes, variability of fasting plasma glucose was associated with the incidence 
of retinopathy 118. In the DCCT, variability of quarterly measured, one-day 7-point 
glucose profi les did not predict incident nephropathy or retinopathy 119, and this 
was also observed in the Epidemiology of Diabetes Interventions and Complications 
(EDIC) 120, which is an extended follow-up of the patients in the DCCT. Variability 
in HbA
1c 
was, however, associated with the incidence of both diabetic nephropathy 
and retinopathy in the DCCT 121, thus linking the variability of long-term glycaemic 
control to the risk of microvascular complications in type 1 diabetes. 
Insulin resistance is another factor that has been implicated in the pathogenesis 
of diabetic nephropathy 122, 123. It has been discussed that pathway-selective insulin 
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resistance is important for the development of diabetic nephropathy 124. In line 
with this, there is some evidence that the metabolic syndrome is associated with 
the prevalence 27 and the incidence 125 of nephropathy in type 1 diabetes. Low birth 
weight 126 and short adult stature 127, 128 are other factors related to insulin resistance 
that have been linked to the risk of diabetic nephropathy. Furthermore, the presence 
of type 2 diabetes in a fi rst-degree relative increases the risk of diabetic nephropathy 
in a patient with type 1 diabetes 129. 
It is, however, obvious that the abovementioned clinical risk factors do not fully 
explain the risk for diabetic nephropathy in type 1 diabetes as there are undoubtedly 
patients with good glycaemic control who still develop this complication. In patients 
with type 1 diabetes, diabetic nephropathy clusters in families 130-132, which indicates 
that there might be an inherited component for the risk of diabetic nephropathy. 
The search for susceptibility genes for diabetic nephropathy using the candidate 
gene approach has identifi ed a number of genes which, however, in most cases 
have not been replicated in other populations. A genome-wide microsatellite scan 
for diabetic nephropathy in type diabetes found linkage to a susceptibility locus 
on chromosome 3q 133. Interestingly, this particular region of the genome has also 
previously been linked to diabetic nephropathy in another linkage analysis that also 
compared siblings with type 1 diabetes but discordant for diabetic nephropathy 134. 
2.2.1.5 Pathogenesis
The molecular mechanisms leading to diabetic nephropathy are probably the 
result of an interaction between genes and the environment. The renin-angiotensin 
system (RAS) seems to play an important role in the pathogenesis of diabetic 
nephropathy. The RAS mediator angiotensin II, which is formed from angiotensin 
I by the angiotensin converting enzyme (ACE), stimulates the production of 
transforming growth factor β (TGF-β). TGF-β may in turn cause extracellular matrix 
overproduction 135 and induce harmful reactive oxygen species 136 in the kidneys. 
Hyperglycaemia induces renal angiotensin II production 137. It is also of note that 
there is both a systemic RAS and a local RAS in the kidneys. Medication that blocks 
the RAS system is used in the treatment of diabetic nephropathy (see section 2.2.1.7). 
Another potential source of tissue damage in diabetes is the accumulation of 
advanced glycation end products (AGEs) by glycation of proteins and lipids and 
these are considered important in the development of diabetic complications 138. 
Besides structural and functional effects, AGEs also induce cellular responses 
via activation of the receptor for AGEs (RAGE) 139 which activates cell signalling 
pathways 140 that may ultimately cause kidney damage. A unifying hypothesis for 
the development of diabetic microvascular complications was suggested by Michael 
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Brownlee, that integrates AGEs, oxidative stress, the polyol pathway (reduction of 
glucose to sorbitol which accumulates in the cells), protein kinase C activation, and 
the hexosamine pathway (glucose conversion to fructose derivates which leads to 
increased production of TGF-β) 141. The core of this hypothesis is that hyperglycaemia 
causes excessive production of mitochondrial superoxide which initiates these 
pathways ultimately leading to tissue damage.
2.2.1.6 Clinical course 
In patients with type 1 diabetes, nephropathy typically presents after 15-20 years 
of living with diabetes, and is preceded by a variable time of microalbuminuria. 
Macroalbuminuria at short duration of type 1 diabetes should raise suspicion of 
the presence of nondiabetic renal disease. Some patients with type 1 diabetes 
develop hyperfi ltration defi ned as a GFR >125-140 ml/min/1.73 m2 at the early 
stages of diabetes. Some studies have even suggested that hyperfi ltration is a risk 
factor for future diabetic nephropathy 142, 143. Some, but not all, of the patients 
with macroalbuminuria will develop ESRD. Patients with macroalbuminuria, and 
especially those with ESRD, are at great risk of cardiovascular events and premature 
death 6-8. Premature death is thus a competing outcome to ESRD in patients with 
type 1 diabetes and macroalbumniuria.
2.2.1.7 Treatment
The treatment of patients with diabetic nephropathy aims to halt the deterioration 
of the kidney function and to reduce the cardiovascular risk. Optimal control of 
glycaemia and blood lipids as well as smoking cessation are important. Dietary 
protein restriction may not only slow down the progression rate of diabetic 
nephropathy 144, 145, but also the progression to ESRD, and may increase survival 
146. The blood pressure should be treated effectively. Optimal blood pressure control 
has repeatedly been shown to slow down the progression of renal disease. In the 
kidneys, ACE-inhibitors reduce the intraglomerular pressure by vasodilation of the 
efferent arteriole because angiotensin II, the main mediator of the RAS system, 
preferentially increases the resistance of the efferent arteriole. ACE-inhibitors and 
angiotensin receptor blockers are the most important antihypertensive medications 
for these patients, because inhibition of the RAS-system in patients with diabetes is 
thought to have benefi cial renal effects beyond blood pressure reduction 147, 148. Of 
note are, however, two recent studies that showed no reduction in the incidence of 
microalbuminuria by inhibitors of the RAS-system in patients with type 1 diabetes 
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and normoalbuminuria 149, 150, suggesting no benefi t of RAS-blockers at least for 
primary prevention of renal disease in diabetes. Renal failure is associated with a 
decrease in the erythropoietin (EPO) secretion from the kidneys and subsequent 
renal anaemia 151, which can be corrected by injections of recombinant human EPO 
or its derivate darbepoetin alfa. Excess correction of the anaemia should however be 
avoided due to concerns for adverse events in patients with kidney failure 152. Renal 
failure also causes profound changes in the calcium and phosphate metabolism with 
deleterious effects on the skeletal tissue due to a decrease in the vitamin D activation 
by the kidney. This condition, referred to as renal osteodystrophy 153, can be treated 
by calcium and vitamin D supplementation and phosphate binders, but sometimes 
there is need for surgical excision of the parathyroid glands to halt the breakdown 
of the skeletal tissue by the secondary and tertiary increase in the secretion of 
parathyroid hormone. Renal failure requires renal replacement therapy; initially 
dialysis (haemodialysis or peritoneal dialysis) followed by kidney transplantation.
2.2.2 Diabetic retinopathy
The retinas of the eyes are commonly affected by diabetes. The fi rst report on 
diabetic retinopathy is from 1935 154. Most patients with type 1 diabetes of 20 years 
duration develop some degree of background retinopathy that most frequently 
involve microaneurysms of the retinal blood vessels. A proportion (up to 42% by 25 
years of type 1 diabetes duration 155) of patients with type 1 diabetes will progress to 
proliferative retinopathy, a condition which is characterised by the growth of new 
blood vessels (neovascularisation) in an attempt to compensate for local ischaemia 
in the retina. If left untreated, proliferative retinopathy can cause blindness. Diabetic 
macular oedema is another diabetes-related entity and this condition is caused by 
hyperpermeability of the retinal capillaries, and may also cause visual impairment 
and blindness. It is of note that diabetic retinopathy is the most common cause of 
blindness in the Western World, but that other causes dominate in the developing 
counties 156. In 1998 in the USA, the cumulative 14-year incidence of blindness due 
to diabetes was 2.4% 157. There is a strong comorbidity with diabetic nephropathy 
in the sense that almost all patients with nephropathy also have retinopathy, but 
retinopathy frequently occur as the sole complication of diabetes. 
Risk factors for diabetic retinopathy are diabetes duration, poor glycaemic 
control, hypertension, and an unfavourable blood lipid profi le. In the DCCT, intensive 
glycaemic treatment reduced the incidence of retinopathy by 76% and slowed the 
progression of existing retinopathy by 54% 103, 158, and the protective effect seemed to 
persist at least 10 years after the end of the trial 159. Blood pressure lowering reduces 
the risk of diabetic retinopathy in type 1 diabetes 160, but the superiority of inhibitors 
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of the RAS-system has been questioned 161, 162. The lipid-lowering agent fenofi brate 
has been shown to reduce the incidence of proliferative retinopathy in type 2 diabetes 
163. Regarding hereditary factors, proliferative retinopathy seems to cluster in siblings 
with type 1 diabetes 164. The pathogenesis of diabetic retinopathy seems to share 
several mechanisms with nephropathy (see section 2.2.1.5): accumulation of sorbitol 
and AGEs, oxidative stress, and PKC activation 165. Neovascularisation, however, 
is a distinct feature of retinopathy and is induced by growth factors, such as the 
vascular endothelial growth factor (VEGF) 166. 
The diagnosis of diabetic retinopathy is based on direct inspection of the retina, 
and does not rely upon intermediate markers such as albuminuria as for the case of 
diabetic nephropathy. Thus, the retina is a true window into the microcirculation. 
Retinas may be examined by fundus photography or direct ophtalmoscopy. Active 
screening and treatment for retinopathy is cost-effective 167 and can reduce the 
incidence of diabetes-related blindness up to 98% 168. 
The treatment of diabetic retinopathy involves the clinical management of risk 
factors. If needed, retinal changes can be treated with laser photocoagulation, a 
procedure that prevents visual loss in patients with proliferative diabetic retinopathy 
169 and/or diabetic macular oedema 170. Inhibition of VEGF is a potential now therapy 
for diabetic proliferative retinopathy 171.
2.2.3 DIABETIC NEUROPATHY
Diabetic neuropathy is a disease of the peripheral nervous system which can be a 
disabling diabetic complication and may reduce the quality of life and increase the 
risk of premature death. Diabetic neuropathy is believed to be a disease of the vasa 
nervorum, the small blood vessels of the nerves; hence neuropathy is considered a 
microvascular complication of diabetes. The clinical defi nition of diabetic neuropathy 
is symptoms or signs of nerve disease in a patient with diabetes when other causes 
than diabetes are excluded 172. Screening for neuropathy in patients with diabetes 
should be performed annually by testing tendon stretch refl exes and sensation in 
the lower extremities 173. Prevalence estimates for diabetic neuropathy differ greatly 
according to the population studied and the defi nitions used. Clinical risk factors 
for diabetic neuropathy include poor glycaemic control, diabetes duration, obesity, 
smoking, lipid profi le, hypertension, and tall stature 173-175. 
There are several types of neuropathies in diabetes. The most common is a 
symmetric chronic sensory polyneuropathy which mainly involves the lower 
extremities and causes loss of sensation and predisposition for ulcers in the feet, 
which ultimately may require limb amputation. There is also an acute, often painful, 
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sensory neuropathy which infrequently occurs at sudden changes in glycaemic 
control. Mononeuropathies also rarely occur. Autonomic diabetic neuropathy affects 
the system that for instance regulates cardiovascular and gastrointestinal refl exes. 
Cardiac autonomic neuropathy is important due to the increase in the risk of sudden 
death, and is characterized by tachycardia at rest (heart rate >100/min) and a drop 
in blood pressure (>20 mmHg) when standing up 173. Cardiac autonomic neuropathy 
frequently causes exercise intolerance (see section 2.4.2.2) and increases the risk 
of sudden death during exercise. Therefore, exclusion of this condition prior to 
the initiation of a heavy exercise program is therefore warranted in patients with 
diabetes 176. Other types of autonomic diabetic neuropathy involve gastroparesis, 
constipation, diarrhoea, erectile dysfunction, and urinary bladder dysfunction. 
There are several measures of cardiac autonomic neuropathy. The classical Ewing 
tests constitute non-invasive interventions to test cardiovascular refl exes during the 
valsalva manoeuvre, deep breathing, standing up, and during sustained handgrip 
177. A more sensitive method is measurement of the barorefl ex sensitivity 178 which 
allows detection of autonomic neuropathy even before signs of clinical organic 
neuropathy are evident. The basic principle behind measurement of the barorefl ex 
sensitivity is the feedback loop from a change in blood pressure into a change in 
heart rate by regulating the vagal nerve activity.
2.2.4 CARDIOVASCULAR DISEASE
Cardiovascular disease (CVD) is the term for clinical manifestations of atherosclerotic 
changes of the large conductance arteries. The clinically most relevant arteries are in 
the heart (coronary heart disease), in the brain (stroke), and in the lower extremities 
(claudication). CVD is not, as the microvascular complications, specifi c to diabetes 
but patients with diabetes have a considerably increased risk thereof. Type 2 diabetes 
may even be a risk factor for a fi rst CVD event equal to that of a previous CVD event 
179. The risk of CVD in patients with type 1 diabetes is also increased compared with 
nondiabetic subjects 180, 181. Diabetic nephropathy markedly increases CVD morbidity 
6 and mortality 7 compared with the absence of nephropathy in type 1 diabetes. 
The reason why renal impairment strongly increases CVD risk – a phenomenon 
called the chronic renocardiac syndrome 182 – is unclear. Diabetic microvascular 
complications and CVD might share common risk factors and according to the 
Steno hypothesis, albuminuria is a marker of general vascular damage in diabetes 
183. Also in nondiabetic subjects, microalbuminuria seems to be a CVD risk factor 
184 thereby extending this phenomenon beyond diabetes. 
CVD in patients with diabetes is associated with some special features that are 
not seen in nondiabetic subjects. Diabetes conferred higher CVD relative risk in 
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women than in men in the Framingham study 185 and subsequent reports 181, 186, 
thus suggesting a loss of gender-associated protection from CVD in patients with 
diabetes. Equal relative CVD risk in both genders with type 1 diabetes has, however, 
also been reported 187, 188. 
The risk factors for CVD in diabetic and nondiabetic subjects do to a large extent 
overlap and include age, blood pressure, blood lipid profi le, smoking, and a family 
history of CVD. The lipid profi le of patients with type 1 diabetes differs from that 
of nondiabetic subjects 189. In patients with well-controlled type 1 diabetes, total 
and LDL-cholesterol are often similar to that of the nondiabetic subjects, but HDL-
cholesterol is often higher. The LDL-cholesterol in patients with type 1 diabetes has 
increased atherogenic properties because of its oxidation 190 and glycation 191 in the 
diabetic milieu. The role of glycaemic control in the context of CVD in patients with 
diabetes is a matter of debate at the moment. In type 2 diabetes, recent randomised 
clinical trials to lower HbA
1c
 by intensive treatment failed to show a reduction in the 
incidence of CVD 192-194, and in one study 193 there was even an apparent increase in 
mortality in the intensive treatment group. A subsequent meta-analysis, however, 
indicated that intensive treatment reduced the incidence of CVD events 195. These 
studies may have been infl uenced by the fact that the patients had a relatively 
long duration of type 2 diabetes at randomisation 196. Notably, in newly diagnosed 
patients with type 2 diabetes, the U.K. Prospective Diabetes Study (UKPDS) showed 
a near-signifi cant (P=0.052) reduction in the incidence of myocardial infarction by 
lowering of HbA
1c 
197, and in a follow-up report intensive treatment showed a clear 
CVD benefi t 198. In the UKPDS risk engine for CVD in patients with type 2 diabetes, 
HbA
1c
 is included as a CVD predictor 199.
2.3 THE METABOLIC SYNDROME
The metabolic syndrome is defi ned as a cluster of cardiovascular risk factors 
that frequently occur together. Initially called syndrome X 200, this condition 
was recognised as the simultaneous fi nding of a disturbed glucose metabolism, 
hypertension, and dyslipidaemia. Insulin resistance has been considered the key 
feature of what today is referred to as the metabolic syndrome 201. The fi rst clinical 
defi nition was presented by the WHO in 1998 202. Since then, several defi nitions of the 
metabolic syndrome have emerged. In 2001, the National Cholesterol and Education 
Program Adult Treatment Panel III (NCEP) introduced a defi nition 203 and in 2005 
the International Diabetes Federation (IDF) introduced the latest defi nition to be 
widely used 204. Table 1 presents the defi nitions in detail. The IDF defi nition differs 
fundamentally from the others by the demand of abdominal obesity. The WHO 
defi nition, on the other hand, is the only to include microalbuminuria. 
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Requirement Multiple options
WHO Diabetes/IGT 
plus two out of:
1.BMI >30 and/or WHR >0.90 (M) or 
>0.85 (W)
2. SBP ≥140 and/or DBP ≥90 mmHg
3. HDL-chol. <0.9 (M) or <1.0 mmol/l (W)
   and/or triglycerides ≥ 1.7 mmol/l
4. Microalbuminuria (UAER ≥20 μg/min)
NCEP Three out of: 1. Diabetes/IGT
2. Waist >102 (M) or >88 cm (W)
3. SBP ≥130 and/or DBP ≥85 mmHg
4. HDL-chol. <1.0 (M) or <1.3 mmol/l (W)
   and/or triglycerides ≥ 1.7 mmol/l
IDF Waist ≥94 cm 
(M) or ≥80 cm 
(W)
and two out of:
1. Diabetes or fasting glucose ≥5.6 mmol/l*
2. SBP ≥130 and/or DBP ≥85 mmHg*
3. HDL-chol. <1.03 (M) or <1.29 mmol/l 
(W)
   and/or triglycerides ≥ 1.7 mmol/l*
Joint 
statement 
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Three out of: 1. Elevated waist circumference (population-
specifi c cut-off values, see IDF for Europe)
2. Triglycerides ≥1.7 mmol/l*
3. HDL-chol. <1.0 (M) or <1.3 (W)*
4. SBP ≥130 mmHg and/or DBP ≥85 
mmHg*
5. Fasting blood glucose ≥5.6 mmol/l*
Table 1. Common defi nitions of the metabolic syndrome. M: men. W: women. *Or treatment for 
hyperglycaemia, hypertension or hyperlipidaemia. 
Type 2 diabetes is in close relation to the metabolic syndrome as one of the 
criteria mention in table 1. The prevalence of the metabolic syndrome increases 
abruptly with the degree of glucose tolerance. In a Finnish cohort, the prevalence 
of the WHO defi nition of the metabolic syndrome was 14.4% in men with normal 
glucose tolerance, 74.0% in case of impaired fasting glucose, and 91.5% if type 2 
diabetes had been diagnosed 206. The metabolic syndrome has also been described 
in Finnish patients with type 1 diabetes, even though the commonly used defi nitions 
do not take type 1 diabetes into consideration. Using the NCEP defi nition, 38% of 
men and 40% of women with type 1 diabetes fulfi lled the criteria for the metabolic 
syndrome which furthermore was associated with poor glycaemic control and a 
higher prevalence of diabetic nephropathy in a cross-sectional setting 27. A similar 
prevalence was reported in Italian patients with type 1 diabetes 207. The cross-
sectional association between the metabolic syndrome and diabetic nephropathy 
was challenged by two prospective studies that showed little predictive value of the 
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metabolic syndrome for cardiovascular disease and diabetic nephropathy in type 
1 diabetes 208, 209. Nevertheless, a recent follow-up study indicated that the NCEP 
defi nition of the metabolic syndrome was predictive of CVD events and mortality, 
and even though the predictive value for development and progression of diabetic 
nephropathy was low, the presence of the metabolic syndrome added upon the 
predictive value of an elevated UAER for CVD events 125.
It can be argued, though, that the metabolic syndrome is redundant. There are 
totally opposing views as to whether the metabolic syndrome serves a purpose 
in clinical medicine 210, 211. The metabolic syndrome can be regarded as merely an 
arbitrary condition with varying cut-off values of a continuous risk relationship 
between the blood glucose concentration and cardiovascular disease and that the 
metabolic syndrome is not an entity of its own 212. As a practical tool for the physician 
treating patients with metabolic disorders, however, the metabolic syndrome is at 
least useful as a reminder that when one cardiovascular metabolic risk factor is 
present, the physician should also test for the rest and treat them. 
2.4 PHYSICAL ACTIVITY
Herodicus (born 480 B.C.), a Greek physician, is considered to have been the fi rst to 
use exercise as a therapy for various diseases 213. Hippocrates, inspired by Herodicus, 
early acknowledged the importance of lifestyle in his work Regimen around 400 
B.C.: “For food and exercise, while possessing opposite qualities, yet work together 
to produce health”. 
Physical activity is the general term for any energy expenditure that result from 
skeletal muscle contractions. Exercise is a component of physical activity and refers 
to planned physical activities aimed to increase the level of physical fi tness, which 
in turn has components of endurance and strength. Activities have a frequency 
(how often performed), an intensity (performed at what level of exertion), and 
a duration (time per session). In this thesis, the term physical activity has been 
preferred to describe the activity behaviour of the patients. 
Quantifi cation of physical activity involves objective measurements, diaries, and 
questionnaires. Each of these methods has distinct benefi ts and limitations. Physical 
activity can be measured by step counters, accelerometers, or heart rate monitors. 
Doubly labelled water is a method using deuterium (2H)- and 18O-labelled water 
to determine the metabolic rate in free-living condition 214. The energy expenditure 
exceeding the basal metabolic rate gives an estimate of the physical activity. Doubly 
labelled water can be used for the validation of physical activity questionnaires 215. 
Objective measurements of physical activity may be regarded more accurate than 
self-report questionnaires 216. Devices measuring activity, however, are generally 
more applicable only to smaller study populations. Such devices also have the 
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potential bias of increased physical activity during days of measurement. Physical 
activity diaries may also have such a bias of increased activity during surveillance. 
For epidemiological studies involving large numbers of patients, physical activity 
questionnaires have often been used due to practical and economical reasons. 
2.4.1 GLUCOSE RESPONSES DURING PHYSICAL ACTIVITY
2.4.1.1 Energy supply
Skeletal muscle tissue has a tremendous energy output potential as the metabolic 
rate in the muscle cells can increase 200-fold during strenuous physical activity 217. 
Accordingly, an effi cient glucose transport system into the muscle cells is essential. 
Muscle glycogen is the principal source of glucose, but glucose from the blood 
circulation is also important. Muscle glycogen stores are usually regenerated in 
0.5-2 h after a prolonged activity and are fully restored within one day by glucose 
from the blood, thus preparing the muscles for the next bout of activity.
For the exercising skeletal muscle tissue, adenosine triphosphate (ATP) is the 
principal fuel currency, and energy is released by the breaking of high-energy 
phosphate bonds resulting in adenosine diphosphate (ADP). The main source of 
ATP during a bout of physical activity varies. Existing ATP in the muscles is depleted 
within one second, and the maintenance of skeletal muscle work depend on constant 
replenishment of ATP by three principal systems 217. The fi rst system is creatine 
phosphate stored in the muscle as a rapid source for rephosphorylation of ADP to 
ATP. This system is independent of oxygen (anaerobic) and only operates for up to 
nine seconds of activity. The second system involves breakdown of muscle glycogen 
to glucose and further to lactic acid during anaerobic glycolysis, a process during 
which ATP is obtained. This lactic acid system is most critical during ten seconds 
up to two minutes of physical activity. This system is limited by accumulation of 
lactic acid in the muscle, which causes a burning sensation. The third and most 
sophisticated system is initiated when the activity exceeds two minutes of duration. 
Hereby, glucose obtained mainly from muscle glycogen deposits, but also from 
the blood, is oxidised in the citric acid (Krebs) cycle to produce ATP. Likewise, 
free fatty acids are degraded and oxidised during β-oxidation to yield ATP. These 
oxygen-dependent processes take place in the mitochondria and the ATP yield per 
molecule of glucose is tenfold to that of the anaerobic lactate system. In real life, 
the temporal boundaries between these three systems is somewhat overlapping. 
Furthermore, a sudden intensity increase during prolonged endurance activities 
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requiring extra ATP may temporarily reactivate the lactate system. The skeletal 
muscle tissue, unlike the liver, lacks the enzyme glucose-6-phosphatase which 
means that muscle glycogen is consumed locally and glucose is not released into 
the bloodstream. The liver, on the other hand, can release glucose into the blood 
by glycogenolysis, and can further synthesise glucose from amino acids and lactate, 
a process called gluconeogenesis. Muscle glycogen constitutes about 130 g and 
typically lasts for 90 minutes of endurance activity without carbohydrate ingestion. 
The ratio of carbohydrate-to-fat energy use by the body varies, from about 40% 
during rest but increases during high-intensity exercise up to 100%. Many factors 
such as the diet content prior to activity, muscle glycogen store depletion, and 
hormone (such as insulin and adrenalin) levels also infl uence the source of energy 
during physical activity.
Skeletal muscle tissue is insulin sensitive. Insulin binds to the insulin receptor 
which causes autophosphorylation of intracellular tyrosine residues. This further 
activates the signal transduction cascade ultimately leading to translocation of the 
glucose transporter 4 (GLUT4) to the cell surface whereby glucose can enter the muscle 
cell. Physical activity causes an acute increase in insulin sensitivity of the skeletal 
muscle cells which facilitates glucose entry 218. Even more important, however, is that 
muscle contractions themselves increase glucose infl ux independently of insulin 219. 
This effect of contraction is also mediated via an increase in GLUT4 translocation to 
the muscle cell surface, but via other intracellular signalling pathways than insulin 220. 
Moreover, the GLUT4 molecules recruited by insulin and contractions seem to derive 
from separate pools of intracellular GLUT4-containing vesicles 221. Insulin resistance 
does not seem to impair the contraction-dependent glucose uptake of glucose to 
the skeletal muscle 222. The mechanism behind increased glucose uptake by muscle 
contractility is somewhat unclear, but nitric oxide produced by the contracting 
muscle is considered important either through increased blood fl ow or through 
a direct effect on GLUT4 translocation to the cell surface 223. Another suggested 
mechanism in contracting skeletal muscle cells is via increased 5’AMP-activated 
protein kinase (AMPK) levels. AMPK is activated by alterations in the ATP/AMP- 
and creatine/phosphocreatine-ratios 224.
2.4.1.2 Hormonal responses in nondiabetic subjects
During physical activity, the secretion of several hormones differ greatly from the 
resting state 217. The extent of these changes depends upon duration and intensity 
of the activity and on the fi tness level of the individual. The main purpose is to 
provide contracting skeletal muscles with nutrients and to maintain a normal blood 
glucose level. The insulin secretion from the pancreas diminishes from the initiation 
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of physical activity and remains lowered throughout the activity. At moderate 
intensity, insulin levels decrease to about half of the level at rest. The levels of 
counterregulatory hormones of insulin, on the other hand, increase during activity. 
Neuroendocrine (sympathetic) refl exes cause a pre-emptive rise in adrenaline and 
noradrenaline already at mental preparation for physical activity. During activity, 
the adrenal medulla continues to secrete adrenaline and noradrenaline. These 
catecholamines stimulate glycogenolysis in the muscles, lipolysis in the adipose 
tissue, and to some extent glucose output from the liver by glycogenolysis and 
gluconeogenesis. Simultaneously, glucagon secretion from the pancreas increases, 
with similar metabolic effects as the catecholamines, especially glycogenolysis and 
gluconeogenesis in the liver. This results in glucose output from the liver, decreased 
peripheral glucose uptake (apart from the skeletal muscles), release of free fatty 
acids to the circulation, and glucose release from glycogen stores in the skeletal 
muscles. Cortisol secretion from the adrenal cortex increases during activity which 
promotes protein catabolism to provide substrates for gluconeogenesis. Growth 
hormone secretion from the pituitary gland increases when the activity exceeds 
40-50 minutes, in turn stimulating lipolysis and also working through multiple 
mechanisms to raise the blood glucose concentration. Water- and electrolyte balance 
during activity is facilitated by an increase both in aldosterone and antidiuretic 
hormone secretion leading to retention of water and sodium ions in the kidneys.
2.4.1.3 Hormonal responses in patients with type 1 diabetes
Insulin is administered exogenously in patients with type 1 diabetes. During 
physical activity, therefore, the physiologic decrease in insulin secretion is absent 
and the amount of circulating insulin depends on the amount and the timing of 
recent insulin injections. Insulin absorption from the site of injection is more rapid 
during physical activity than at rest due to increased blood circulation, especially 
in the thigh 225. Also in patients with diabetes, physical activity increases insulin 
sensitivity. If these aspects are not taken into consideration, there is considerable risk 
of hypoglycaemia during or after physical activity in a patient with type 1 diabetes. 
Relative hyperinsulinaemia during physical activity increases the skeletal muscle 
glucose uptake from the circulation disproportionately in relation to the use of 
muscle glycogen as the source of glucose. Insulin also inhibits lipolysis in the adipose 
tissue, thus increasing the carbohydrate demand as the skeletal muscle fuel source. 
In addition, with increasing duration of type 1 diabetes, the glucagon response is 
blunted 226 which in concert with relative hyperinsulinaemia impairs an adequate 
glucose output from the liver to the circulation during physical activity. Autonomic 
neuropathy may in turn damage the sympathetic nervous system resulting in a 
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decreased adrenergic response during physical activity, which can also cause 
hypoglycaemia during activity. Symptoms of hypoglycaemia can further be silenced 
by autonomic neuropathy, which can result in severe hypoglycaemia.
2.4.1.4 Acute effect on blood glucose
During physical activity the blood glucose concentration in a patient with type 1 
diabetes can remain unchanged, decrease, or increase depending on numerous 
factors that infl uence the amount of circulating insulin and the availability of 
glucose. Before the start of physical activity the blood glucose concentration should 
be between 5.6 and 16.7 mmol/l and in case of ketosis no higher than 13.9 mmol/l 
176. If the blood glucose is below 5.6 mmol/l, carbohydrate supplementation (15-30g 
depending on activity) should be ingested to prevent hypoglycaemia but this is not 
an unconditional rule for all types of activities, especially those of high intensity 
and short duration. Hyperglycaemia should be corrected with short-acting insulin, 
because physical activity during hypoinsulinaemia can cause a further rise in blood 
glucose concentration and, in a worst case scenario, even lead to ketoacidosis.
In nondiabetic individuals, the blood glucose concentrations are strictly 
controlled during physical activity resulting in normal blood glucose levels both 
during and after activity. An exception is high intensity activities, which can cause 
transient hyperglycaemia mostly due to a massive adrenergic activation of the liver 
glucose output. A rise in the insulin secretion at the cessation of activity rapidly 
normalises such elevated blood glucose levels in nondiabetic subjects. In patients 
with type 1 diabetes, however, the absence of a physiologic insulin response may 
cause blood levels to rise substantially during activities of high intensity 227. A bolus of 
short-acting insulin may be required after such activities, with subsequent frequent 
blood glucose measurements to prevent hypoglycaemia. 
2.4.1.5 Hypoglycaemia
Hypoglycaemia during or after physical activity, or fear thereof, is often a barrier for 
a patient with type 1 diabetes to engage in physical activity 228, 229. Hypoglycaemia can 
be defi ned as a blood glucose concentration ≤3.9 mmol/l 230, but the threshold for 
symptomatic hypoglycaemia varies both inter- and intraindividually. Hypoglycaemia 
can in the broad perspective be regarded as the main limiting factor for achievement 
of good glycaemic control in type 1 diabetes 231 and this is true for all interventions 
that lower blood glucose, mainly insulin treatment and physical activity. 
The mechanisms of hypoglycaemia during or after physical activity mainly 
include the circulating insulin concentration, the carbohydrate availability, the 
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replenishment of muscle glycogen stores, the effect of the counterregulatory 
hormones, and the awareness of symptoms of hypoglycaemia. 
To prevent hypoglycaemia, one should remember that the peak effect of most 
short-acting insulin preparations appears 1.5-2 h after the injection, and rapid-
acting insulin analogues peak at 60 min after injection. The site of injection 225 
and the ambient temperature 232 may affect insulin absorption during activity. 
Prandial insulin doses previous to physical activity may be reduced to mimic the 
physiologic decrease in insulin secretion during physical activity in nondiabetic 
subjects. After the activity, the next prandial insulin dose may also have to be reduced 
to account for the acute increase in insulin sensitivity. The magnitude of reduction 
in insulin dose depends upon the type, intensity, and duration of physical activity 
and probably also on the individual responses to physical activity. For instance, 
a moderate intensity activity for 30 min may require only 10-20% reduction in 
prandial insulin, but a high-intensity activity may require up to 60% reduction 233. 
Basal insulin doses may also be reduced at days of activities with long duration. 
During physical activity, routine carbohydrate supplementation is usually needed 
only if the duration is >1 h, but can be needed for activities of shorter duration in 
case of relative hyperinsulinaemia. After activity, carbohydrate ingestion is usually 
recommended because of the increased demand of glucose to replenish muscle, 
and sometimes also liver, glycogen stores. The amount of carbohydrate is often 
15-30 g and can be taken as solid food, fl uids, or gels. Fluids containing 5-10% of 
carbohydrate are rapidly absorbed 233, because the carbohydrate concentration of 
fl uids is important for the rate of gastric emptying 234. 
Muscle glycogen stores are replenished from blood glucose after physical 
activity at a rate that is highest 0.5-2 h after activity but can continue up to 24 
h, thus (together with the acute increase in insulin sensitivity) increasing the risk 
of hypoglycaemia many hours, typically during the night, after physical activity. 
Immediate carbohydrate ingestion after activity may decrease this risk. 235.
Counterregulatory hormones to insulin prevent hypoglycaemia in nondiabetic 
subjects, but in patients with type 1 diabetes this response may be abnormal. The 
glucagon response to hypoglycaemia is blunted in patients with type 1 diabetes 226. 
The adrenergic response may be defective in patients with autonomic neuropathy, 
which leads both to a decreased ability to increase the blood glucose concentration 
and, perhaps even more importantly, to decreased symptoms of hypoglycaemia 
which are mostly mediated by the adrenergic system. Even in patients with type 
1 diabetes who otherwise have a functioning counterregulatory hormone system, 
an episode of hypoglycaemia will reduce this response even for several days, a 
phenomenon called “hypoglycaemia-associated autonomic failure” 236. An episode 
of hypoglycaemia will have consequences for any forthcoming (next day) physical 
activity in form of a reduced response of counterregulatory hormones during physical 
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activity and subsequent risk of hypoglycaemia during, or after, activity 237. Moreover, 
physical activity in itself has also been reported to blunt these counterregulatory 
hormone responses during a subsequent hypoglycaemic event 238. This may lead to 
a vicious cycle of recurrent hypoglycaemic episodes that can cause a highly instable 
glycaemic control with alternating hypoglycaemia and rebound hyperglycaemia 
due to the overcorrection of blood glucose concentrations. An interesting detail is 
that women with type 1 diabetes seems to have better counterregulatory hormone 
responses to physical activity than men 239.
To decrease the risk of hypoglycaemia after physical activity, a 10 s maximal 
sprint at the end of a session of moderate-intense aerobic activity has been proposed 
240. This approach takes advantage of the counterregulatory hormones, especially 
the catecholamines that are secreted during high-intense exercise. There is some 
evidence for higher post-exercise blood glucose concentrations using the 10 s 
maximal sprint both when performed at the end 240 and at the beginning 241 of a 
bout of moderate-intense physical activity. There are, however, no available data 
investigating the actual incidence of hypoglycaemic events after physical activity 
with the 10 s maximal sprint.
2.4.2 PHYSICAL ACTIVITY AND TREATMENT OF TYPE 1 DIABETES 
According to the recommendations from the American Diabetes Association, 
patients with diabetes should engage in regular physical activity to improve their 
cardiovascular risk profi le 176. The effect of physical activity regarding the risk of 
microvascular diabetic complications is to a large extent unknown. Glycaemic 
control is a major risk factor for microvascular diabetic complications. In type 2 
diabetes, the consensus is that physical activity improves the long-term glycaemic 
control 10, 242. In type 1 diabetes the evidence is inconclusive, however. 
2.4.2.1 Glycaemic control in type 1 diabetes
There are intervention and cross-sectional association studies investigating the 
relationship between physical activity and glycaemic control in patients with type 
1 diabetes. Available physical activity intervention studies 11, 12, 243-258 are presented 
in Table 2. Most of these studies showed no benefi cial effect on HbA
1c
, HbA
1
, or 
glucose values. These studies were performed predominantly during the 1970-80s 
and thus the treatment does not fully represent the insulin regimen of today. Most 
of the studies employed a small number of patients and short time of intervention. A 
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more recent cross-sectional study showed no association between a physical activity 
score and HbA
1c
 in adult patients with type 1 diabetes, but the validation of the score 
was not reported 259. Cross-sectional data from a large paediatric population, on 
the other hand, showed that patients with a frequency of regular physical activity 
<1 time/week had higher HbA
1c
 than those with a frequency 1-2 and ≥3 times/
week, while the latter two groups had similar HbA
1c
 260. A limitation with these 
cross-sectional association studies is that the causal effect of physical activity is 
uncertain because physical activity is in itself usually associated with other lifestyle 
factors and diabetes treatment behaviour, which creates problems with collinearity. 
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2.4.2.2 Diabetic complications
Physical activity and diabetic complications might have multiple interactions. First, 
the diabetic complications, being chronic devastating illnesses, can be thought to 
reduce the physical activity of affected patients. Second, physical activity results in 
multiple responses that all have been implicated in the pathogenesis of diabetic 
complications (Figure 1) and could therefore reduce the incidence and progression 
of the diabetic complications. A caveat, on the other hand, is that physical activity 
in theory also could be detrimental for patients with diabetic complications.
Figure 1. Potential chronic responses to physical activity 
There are some specifi c physical activity recommendations for patients affected 
by diabetic complications. The American Diabetes Association recommends176 that 
patients with proliferative retinopathy should avoid activities that involve valsalva 
manoeuvres because of the risk of vitreous haemorrhage. Loss of sensation in 
the feet due to diabetic neuropathy promotes the choice of non-weight-bearing 
activities. Autonomic neuropathy, and especially cardiac autonomic neuropathy, 
should be diagnosed prior to initiation of a physical activity program because of 
exercise intolerance and increased risk of sudden death during physical activity. 
Cardiovascular evaluation may also be needed depending on age, duration of 
diabetes, and presence of cardiovascular risk factors. Diabetic nephropathy is 
thought to self-limit physical activity due to a reduced capability for physical activity 
176. 
It has been shown that patients with type 1 diabetes have decreased aerobic work 
capacity if they have increased UAER, and similar impairment was shown both 
for patients with micro- and macroalbuminuria compared with normal UAER 261. 
Conversely, exercise has been shown to induce transient albuminuria in patients with 
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type 1 diabetes with normoalbuminuria, and also a transiently worsened albuminuria 
in those with microalbuminuria was reported 262, 263. This phenomenon is also well-
known in nondiabetic subjects and is thought to result from haemodynamic factors 
such as increased glomerular pressure and increased glomerular permeability for 
albumin264, 265. There have been concerns that the renal function of patients with 
diabetic nephropathy may be harmed by moderate to heavy physical activity266. 
Recent follow-up data showed that physically active patients with type 2 diabetes 
and macroalbuminuria had increased total and CVD mortality 267. Some patients with 
type 1 diabetes seem to have an exaggerated albuminuria response to an exercise 
test compared with nondiabetic subjects263. Improved glycaemic control by insulin 
pump therapy for three weeks reduced the exercise albuminuria response of patients 
with type 1 diabetes to that of nondiabetic controls 268. An exercise albuminuria 
provocation test might reveal early signs of future renal involvement in patients 
with type 1 diabetes and normal UAER at rest 262, 263. There are some data that 
support a prognostic value of exercise-induced albuminuria for the development of 
microalbuminuria in patients with normoalbuminuria, and it was even suggested 
that repeated albuminuria testing thus could be substituted by one single exercise 
test in patients with normoalbuminuria 269. This is, however, a controversial issue 
as another study showed that the exercise albuminuria response do not predict 
new-onset microalbuminuria 270.    
The physical activity of patients with type 1 diabetes and diabetic complications 
has not been extensively studied. A cross-sectional study in type 1 diabetes reported 
an association between lower physical activity and higher prevalence of diabetic 
neuropathy, retinopathy, and nephropathy 271. The causal relationship between 
physical activity and complication status was, however, unclear due to the cross-
sectional design. Higher level of past physical activity during adolescence was, 
interestingly, associated with lower prevalence of nephropathy and neuropathy in 
men, but not in women, with type 1 diabetes which could indicate a protective effect of 
physical activity on future risk of diabetic complications 271. Mortality in patients with 
type 1 diabetes was in a longitudinal study inversely associated with physical activity 
even when controlling for the presence of diabetic complications 272. Regarding 
diabetic complications there are no longitudinal studies, however premature 
mortality in type 1 diabetes is mainly attributable to the diabetic complications and 
therefore indirectly supports a protective effect of physical activity on development 
and/or progression of the diabetic complications. The hardest level of evidence for 
such a protective role would come from a physical activity intervention study with 
prospective assessment of the incidence of diabetic complications, but this is an 
laborious study setting requiring large number of patients undergoing intervention 
and extensive follow-up. There are some intervention studies on intermediary 
outcomes for diabetic complications. Endothelial dysfunction in the forearm of 
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patients with type 1 diabetes improved by 4 months of aerobic exercise training, 
and interestingly the vasodilatory response of the ocular vasculature also improved 
with theoretical implications for diabetic retinopathy 273. 
2.4.3 PHYSICAL FITNESS
The aerobic capacity of patients with type 1 diabetes is either decreased 274, 275 
or similar 276, 277 compared with healthy controls. There are no available studies 
regarding the relative strength fi tness of patients with type 1 diabetes. The 
diabetic milieu could be thought to reduce the exercise capacity by changes in the 
cardiovascular, respiratory, muscular, and neural systems. Pulmonary changes due 
to diabetes, such as thickening of the alveolar wall, could impair the gas exchange 
during physical activity 278. Diabetes could also affect the microcirculation of the 
skeletal muscle 279. Diabetic complications decrease the exercise capacity. Patients 
with type 1 diabetes and micro- and macroalbuminuria have lower maximal exercise 
capacity as compared with patients with normal UAER 261. Diabetic nephropathy and 
retinopathy in patients with type 2 diabetes was associated with reduced exercise 
capacity 280. 
A higher aerobic capacity in patients with type 1 diabetes has been linked to 
better glycaemic control 276, 281 and to a more benefi cial blood lipid profi le 281. A 
more recent study of consecutive patients at a diabetes outpatient clinic, on the 
other hand, reported that patients with higher aerobic capacity had higher HbA
1c
 
while patients with higher strength capacity had lower HbA
1c 
282.           
2.4.4 GENETIC FACTORS AND RESPONSES TO PHYSICAL ACTIVITY
The magnitude of responses to physical training are individual and these differences 
at least partly depend on heritable factors 283. VO
2max
, for example, increase in 
response to training in a variable fashion with familial resemblance 284. A genome-
wide scan for the increase in VO
2max
 in previously sedentary healthy subjects during 
a physical activity intervention in the HERITAGE study revealed linkage to several 
genetic loci that are associated with the magnitude of improvement in aerobic fi tness 
285. Some genes have been linked to responses in glucose metabolism, for instance the 
peroxisome proliferator-activated receptor γ (PPARγ) gene for which the Ala-allele 
of the functional Pro12Ala polymorphism has been associated with improvement of 
insulin sensitivity by physical training in nondiabetic subjects 286, 287 and lowering 
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of the fasting plasma glucose concentrations in patients with type 2 diabetes 288. 
The knowledge about genes affecting training outcomes is rapidly increasing and 
yearly updates in this fi eld are published 289. 
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3. AIMS OF THE STUDY
The role of physical activity and physical fi tness for patients with type 1 diabetes 
has not been extensively studied and there is controversy regarding the connection 
with the long-term glycaemic control. The relationship between physical activity and 
the diabetic complications in patients with type 1 diabetes is also not well known, 
and especially the impact of early stages of diabetic nephropathy has gained little 
attention. 
The main aims of the study were the following:
I  To investigate the associations between diabetic complications and physical 
activity in patients with type 1 diabetes with special attention to the degree 
of involvement of renal, retinal, and cardiovascular complications.
II To evaluate the associations between physical activity and long-term 
glycaemic control (HbA
1c
) in patients with type 1 diabetes
III To study the intrapersonal variability in HbA
1c
 in type 1 diabetes with respect 
to incidence of diabetic complications and physical activity.
IV To study the association between physical activity and the metabolic 
syndrome in patients with type 1 diabetes, and to assess the impact of the 
peroxisome proliferator-activated receptor γ (PPARγ) polymorphism. 
V To compare the aerobic and strength capacities of patients with type 1 diabetes 
to that of healthy controls, and additionally to assess the associations between 
physical fi tness and long-term glycaemic control. 
43
  4. SUBJECTS AND STUDY DESIGN
All patients included in this thesis are participants in the Finnish Diabetic 
Nephropathy (FinnDiane) Study. The subjects in study V are in addition participants 
in a substudy of the FinnDiane, called the IDentifi cation of EArly mechanisms in 
the pathogenesis of diabetic Late complications (IDEAL) Study.
4.1 THE FINNDIANE STUDY
The FinnDiane Study was initiated in 1997 to answer an important clinical question: 
why do one third of patients with type 1 diabetes get diabetic nephropathy? The study 
uses a wide approach and is designed to identify clinical, genetic, environmental, and 
metabolic risk factors for diabetic late complications in patients with type 1 diabetes, 
with an emphasis on diabetic nephropathy. In addition, data on retinopathy and 
cardiovascular disease (CVD) are collected. The FinnDiane Study is a nationwide 
multicenter study with study centres distributed across Finland (Figure 2), which 
include all fi ve university central hospitals, all 16 central hospitals, most (N=27) 
regional hospitals, as well as 31 primary health care centres. At the moment, about 
4700 patients have been recruited. As the total number of patients with type 1 
diabetes in Finland is about 30 000, a total of 16% of the Finnish type 1 diabetic 
population have been recruited to the FinnDiane Study. 
 
 Figure 2.Municipalities with FinnDiane Study centres in Finland.
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The FinnDiane Study has a prospective design. Follow-up data has been collected 
since the year of 2004. The majority of the data in this thesis (studies I, II, and IV) 
report cross-sectional fi ndings from the baseline visit. Study III take advantage of 
the prospectively collected data regarding development and progression of diabetic 
nephropathy and CVD. FinnDiane investigators reviewed medical fi les at the local 
study centres to verify possible occurrence of  renal and cardiovascular outcomes 
during the follow-up time. 
Type 1 diabetes was defi ned in all studies as age at onset of diabetes <35 years 
and permanent insulin treatment initiated within one year of diagnosis. In addition, 
in study II we required C-peptide negativity defi ned as <0.2 nmol/l. The age at onset 
has been shown to be a reliable discriminator between type 1 and type 2 diabetes 
in the Finnish population 290. 
At baseline, patients in the FinnDiane Study fulfi lling the abovementioned criteria 
for type 1 diabetes (N=3968) had a slight male predominance (51.2% men), mean 
age 37.8±11.5 years (range 18-78 years), duration of diabetes 23.0±12.0 years, BMI 
25.0±3.5 kg/m2, and HbA
1c
 8.5±1.5%. Regarding the kidney disease status, 56.7% had 
normoalbuminuria, 12.5% had microalbuminuria, 14.5% had macroalbuminuria, 
and 6.9% had ESRD. In 9.4% of the patients the renal status could not be defi ned 
because of insuffi cient number of urine collections. Furthermore, 9.8% had CVD 
and 35.3% had laser-treated (proliferative) retinopathy.
The number of patients in studies I-IV varied due to several reasons. The major 
factor is the continuous recruitment of new patients as the study is ongoing. In study 
II the requirement of C-peptide negativity excluded also patients with missing values. 
The main outcomes in the studies also caused some differences in inclusion criteria, 
for instance the metabolic syndrome requires complete data on lipid profi le, blood 
pressure, and obesity. Study III is prospective and includes all patients with data 
on renal status both at baseline and at follow-up, and available data on physical 
activity was not a prerequisite for inclusion in that study.  
All patients in the FinnDiane study did not have data on physical activity. Of 
the patients that fulfi lled the abovementioned criteria for type 1 diabetes, 1945 
(49%) had data on physical activity. In Table 3, patients with and without data on 
physical activity are compared showing an overrepresentation of men and patients 
with diabetic nephropathy in patients with unavailable data, but no corresponding 
differences in age and BMI. The distribution of patients with microalbuminuria 
was also similar. 
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Data available Data unavailable P-value
Patients (N) 1945 2023 -
Gender (% men) 47.8 54.2 <0.01
Age (yrs) 38.0±11.7 37.6±11.3 0.330
Duration of diabetes (yrs) 22.9±12.3 23.1±11.8 0.660
BMI (kg/m2) 25.0±3.4 25.0±3.6 0.822
Microalbuminuria (%) 13.9 13.7 0.883
Macroalbuminuria (%) 12.9 18.7 <0.01
ESRD (%) 3.4 9.9 <0.01
Table 3. Characteristics for patients comparing the availability of data on physical activity in the 
FinnDiane Study. 
4.2 THE IDEAL SUBSTUDY
In 2003, the IDEAL-substudy of the FinnDiane Study was launched to search 
for early markers for diabetic complications in patients with type 1 diabetes. The 
FinnDiane Study was not suitable for this purpose due to the long mean duration 
of diabetes in most patients. Therefore, there was a need to recruit patients with a 
short duration of type 1 diabetes. In addition, there was a desire for a true population-
based cohort. 
A query at the Finnish Social Insurance Institution, which is thought to have a 
registry covering 98% of all patients with type 1 diabetes in Finland 291, identifi ed 
400 patients with type 1 diabetes (code E10 in the ICD-10 classifi cation) living in the 
Helsinki area with an age of 18 to 35 years and duration of diabetes 6 to 12 years. 
The high completeness of the registry is facilitated by full reimbursement for insulin 
for patients with type 1 diabetes. Of these, 165 patients responded and were willing 
to participate. After excluding pregnant women and using a tight defi nition of type 
1 diabetes (unstimulated C-peptide <0.3 nmol/l and insulin treatment within one 
year of diabetes diagnosis), the fi nal number of patients were 140 and constituted 
the IDEAL cohort. At recruitment, the patients were 54.1% men with mean age 
27.1±5.7 years, duration of diabetes 9.6±4.3 years, BMI 24.9±4.2 kg/m2, and HbA
1c
 
8.1±1.3%. No selection was made with respect to diabetic complication status, and 
due to the short duration of diabetes most patients were free from complications. 
Accordingly, of the 140 patients at baseline only three had microalbuminuria and 
one had macroalbuminuria, and none had clinically evident CVD. 
The IDEAL Study has a prospective study design. The patients undergo a vast 
amount of testing for cardiac autonomous neuropathy, ambulatory blood pressure 
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measurements, and echocardiography. In addition, physical fi tness is assessed 
by spiroergometry. The development of diabetic complications is followed up by 
quarterly performed urine collections and yearly fundus photographs of the retinas. 
4.3 ETHICS ASPECTS
The FinnDiane Study and the IDEAL substudy are purely observational, and thus 
no interventions which could be harmful are performed. The patients give written 
informed consent to participate. The major disadvantage for the participants is 
the time consumed by the study visit and completing questionnaires, as well as 
possible pain from venapuncture when drawing blood samples. For the patients 
with diabetes, an overnight fast was not required prior to blood sampling. The 
research protocol was in accordance with the Declaration of Helsinki (as revised in 
the year 2000) and approved by the local ethical committees of the participating 
study centres. 
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5. METHODS
5.1 FINNDIANE STUDY PROTOCOL
5.1.1 PATIENT RECRUITMENT
In the FinnDiane Study, patients were recruited by nurses and physicians at general, 
diabetes, and renal outpatient clinics at the local study centres. As sole inclusion 
criterion type 1 diabetes was required (code E10 in the ICD-10 classifi cation), with 
no prerequisite regarding renal disease or other diabetic complications.
5.1.2 MEDICAL HISTORY
The physician at the study centre completed, based on the patient´s medical records, 
a standardised check-list regarding medication, year of onset of diabetes and year 
of initiation of permanent insulin treatment. Renal status was categorised as 
microalbuminuria, macroalbuminuria, or ESRD (dialysis or kidney transplantation) 
and retinopathy status as any retinopathy or retinal laser photocoagulation. CVD 
was assessed as diagnosis of coronary heart disease as well as occurrence of any 
hard CVD end-point: myocardial infarction, coronary artery by-pass surgery or 
angioplasty, stroke (ischaemic or haemorrhagic), amputations in the lower limbs, 
and peripheral artery by-pass surgery or angioplasty. 
5.1.3 ANTHROPOMETRIC MEASUREMENTS
Weight and height were measured with the patient wearing light clothing. Waist 
circumference was measured halfway between the lowest ribs and the iliac crest. 
Hip circumference was measured at the major trochanters of the femurs. Blood 
pressure was measured twice after a 10 minute of rest from the brachial artery in a 
sitting position using a manual sphygmomanometer or an automated blood pressure 
measurement device in accordance to the clinical practice at the local study centres.
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5.1.4 LIFESTYLE AND SOCIOECONOMIC FACTORS
The patients completed a self-report questionnaire regarding current and previous 
smoking, as well as dose (cigarettes, pipes or cigars per day) and duration (years) of 
smoking. Current alcohol consumption was asked as average weekly amount of beer 
(as 33 cl bottle), wine (as glass), or strong spirits (as 10 cl). Level of education and 
the current occupation were asked, and in case of retirement whether it was due to 
disability pension and in that case also the underlying diagnosis. Possible current 
unemployment and its duration were also reported. The patients were categorised 
regarding their socioeconomic status as: unskilled/skilled blue collar workers, lower/
upper white collar, farmers, and others.  
5.1.5 LABORATORY MEASUREMENTS AND ASSAYS
Blood was drawn and one 24h urine collection was performed for central laboratory 
measurements. In addition, from the local study centres the most recent HbA
1c
 value 
and lipid profi le (total-, HDL-, LDL-cholesterol, and triglycerides) were obtained, 
as well as the three most recent values for UAER in either overnight or 24h urine 
collections. HbA
1c
 was measured with a high performance liquid chromatography 
(HPLC) method. In study III, HbA
1c
 measurements by standardised assays from the 
local study centres were also used. C-peptide was measured with radioimmunoassay 
(RIA). The serum lipids were measured in Prof. Marja-Riitta Taskinen´s laboratory 
at the University of Helsinki, Division of Cardiology, by automated enzymatic 
methods with a Cobas Mira analyser. The LDL cholesterol was derived by the 
Friedewald formula 292. Serum creatinine was measured with a kinetic Jaffé reaction 
until 7th January 2002, thereafter by a photometric, enzymatic method (Hitachi 917 
or Modular analyser, Boehring Mannheim/Roche Diagnostics, Basel, Switzerland). 
Urinary albumin concentration was measured with RIA until 1st of November 2002, 
thereafter by immunoturbidimetry. Insulin sensitivity was estimated by a formula 
for estimated glucose disposal rate (eGDR) originally developed for patients with 
type 1 diabetes based on insulin clamp measurements 293. The formula was modifi ed 
for the use of HbA
1c
, not HbA
1
:
(1) eGDR = 24.4 - 12.97(WHR) - 3.39(hypertension) - 0.60(HbA
1c
)
where hypertension is designated 1 if blood pressure ≥140/90 or antihypertensive 
medication, otherwise 0. HbA
1c
 is given as %. WHR: waist-to-hip ratio.
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5.1.6 GENETIC ANALYSES
In study IV, genetic data for the PPARγ Pro12Ala polymorphism is presented. 
Genomic DNA was extracted from leukocytes using Gentra Systems Puregene DNA 
isolation kits (Gentra Systems, Minneapolis, MN, USA). In some of the older 
samples, the standard phenol extraction method was used in order to get a better 
DNA yield. Extracted DNA was stored at –20°C until required for genotyping. 
The Pro12Ala (rs1801282) polymorphism of the PPARγ gene was genotyped using 
fl uorogenic 5´ nuclease allelic discrimination chemistry (TaqMan®) with an ABI 
Prism® 7900 Sequence Detection System (Applied Biosystems, Foster City, CA, 
USA). The assay mix containing primers and probes was designed by applied 
Biosystems. The genotyping success rate was 99%. All duplicated samples were 
coherent and the marker was in Hardy-Weinberg equilibrium.
5.2 ASSESSMENT OF PHYSICAL ACTIVITY
Leisure-time physical activity (LTPA) was assessed by a self-report questionnaire. 
The validity and reproducibility of the questionnaire has previously been described 
294, 295. This questionnaire was originally developed from the Minnesota Leisure Time 
Activity Questionnaire 296 — which is validated against doubly labelled water 215 — to 
the Finnish setting for use in the Kuopio Ischemic Heart Disease Risk Factor Study 
(KIHD) 297. The Finnish conversion had been based on results regarding physical 
activity from the Mini-Finland survey 298 to ensure appropriate types of activities in 
the questionnaire due to possible cultural and climate-related differences between 
Finland and USA. The questionnaire, called 12-month KIHD Leisure-Time Physical 
Activity Questionnaire, contains a section of questions of general type, frequency, 
duration, and intensity of LTPA. Additionally, a second section asks specifi c details 
on frequency (times per month), duration per session, and intensity (graded 0-3) 
for 21 types of predefi ned activities retrospectively from the past 12 months. The 
intensity grading was defi ned as follows: 0: no shortness of breath, no sweating; 1: 
slight shortness of breath, no sweating; 2: shortness of breath, slight sweating; 3: 
heavy shortness of breath, profuse sweating. 
Based on intensity level, each of the 21 activities can be assigned a specifi c 
metabolic equivalent (MET) value. MET is a widely used unit for energy expenditure 
both in exercise practice and in research and is defi ned as multiples of the energy 
expenditure at rest, which approximates an oxygen consumption of 3.5 ml/kg/
min or about 1 kcal/kg/h 299. For instance, light walking is assigned 3 MET, brisk 
walking 5-7 MET, and moderate jogging 8-10 MET. The use MET- instead of kcal-
based energy expenditure has the great advantage of being independent of gender, 
body mass, and age because MET always relates to the resting energy expenditure. 
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The amount of LTPA is usually expressed as MET during a time-period, and in this 
thesis the total amount of LTPA is given as MET hours per week (MET*h/week). 
For quantifi cation of physical activity, MET per time unit has the advantage of 
being a continuous variable, thus with more statistical power than for example the 
frequency or intensity categorical variables in the KIHD 12-month questionnaire.
In this thesis, the patients were grouped based on their LTPA into sedentary (<10 
MET*h/week), moderately active (10-40 MET*h/week), and active (>40 MET*h/
week). The cutoff value chosen to represent a sedentary lifestyle was defi ned as 
LTPA lower than the minimum given by international recommendations 300, that 
is moderate physical activity (about 5 MET) for 30 minutes on most days of the 
week (four days), which equals 10 MET*h/week. 
5.3 MEASUREMENT OF PHYSICAL FITNESS
5.3.1 PRE-PARTICIPATION SCREENING FOR EXERCISE TESTING
The participants reported to the laboratory approximately 2 hours post meal 
consumption with normal medication, and after at least 24 hours without alcohol 
ingestion and ≥12 h after physical exercise. They fi lled and signed the Physical 
Activity Readiness Questionnaire to reveal possible contraindications to exercise. 
A 12-lead ECG in a supine position, height, weight, waist and hip circumference 
were measured. The lung function was determined by fl ow-volume spirometry 
testing (Medikro Spiro 2000, Medikro, Kuopio, Finland). A physician confi rmed 
the patient´s suitability for exercise testing. A fi ngertip capillary blood sample was 
analyzed before the exercise test to maintain blood glucose concentration within an 
acceptable range (5.6-16.7 mmol/l) for exercise, in accordance to guidelines 176. In 
case of lower blood glucose the subjects were given oral glucose supplementation, 
and in case of hyperglycaemia the subjects injected the insulin they routinely use. 
Blood glucose measurements were repeated until within acceptable range. A blood 
glucose measurement was repeated 10 minutes after exercise. Diabetic complication 
status was not an exclusion criterion because none of the patients had overt diabetic 
nephropathy or cardiovascular disease in this young population with short duration 
of type 1 diabetes.
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5.3.2 SPIROERGOMETRY PROTOCOL
The aerobic physical fi tness level of the patients was measured with spiroergometry, 
which is a clinical exercise tolerance test with simultaneous respiratory gas 
measurements. The cycle ergometer (Monark 839 E, Monark Exercise AB, 
Vansbro, Sweden) exercise test was performed with a step incremental protocol. The 
test began with a 3 min rest while sitting on the cycle ergometer. Then, the subjects 
began with 5 min baseline unloaded cycling, after which the step incremental exercise 
protocol was initiated (30 W/3 min for women and 40 W/3 min for men), and the 
subjects continued exercising until volitional fatigue. The criterion for fatigue was 
inability to maintain pedalling cadence at the minimum of 60 rpm. The immediate 
recovery of the subjects after cessation of the test was followed for 3 min during 
unloaded cycling. 
Heart rate (HR) and ECG were continuously monitored by a 12-lead (Marquette 
Max-1, Marquette Electronics, Milwaukee, WI, USA). Arterial blood pressure (BP) 
was measured by sphygmomanometer from the brachial artery at rest, at the end 
of each work rate and after the 3-minute recovery period. Ventilation (V E) and 
alveolar gas exchange were measured breath-by-breath throughout the test protocol. 
The subjects breathed through a facemask (Hans Rudolph Inc., Kansas City, MO, 
USA) connected to a low-deadspace (30 ml) low-resistance turbine (Triple V, 
Jaeger Mijnhardt, Bunnik, The Netherlands) for measurement of inspiratory and 
expiratory volumes and fl ow. The turbine was calibrated before each test by using 
a syringe of known volume (3.00 L, Hans Rudolph Inc., Kansas City, MO, USA). 
Inspired and expired gases were sampled continuously at the mouth and analyzed 
for concentrations of O
2
, CO
2
, N
2
, and Ar by mass spectrometry (AMIS 2000, 
Innovision A/S, Odense, Denmark) after calibration with precision analyzed gas 
mixtures. Raw data were transferred to a computer, which aligned concentrations 
with volume data to build a profi le of each breath. Breath-by-breath alveolar gas 
exchange was calculated by using the AMIS algorithms. The alveolar gas exchange 
data were interpolated to give values in 1 s intervals. The averaged values of the 
last 30 s at every work rate were chosen to represent a given work rate. Maximal 
aerobic capacity (V O
2max
) was determined as the highest value for a moving 60 s 
“window”. Anaerobic threshold (AT) and respiratory compensation point (RCP) 
were determined with the V-slope method. To determine ventilatory effi ciency, V
E was plotted against CO
2
 production (V CO
2
) and a linear regression slope was 
calculated for this ratio from rest up to RCP and to peak exercise. 
5.3.3 MUSCLE STRENGTH TESTING
Hand-grip strength was tested twice from both hands by a hydraulic hand 
dynamometer (Baseline, Irvington, NY, USA), and the highest value was used. 
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Lower-limb strength was tested by three squat jumps and three counter movement 
jumps. In the squat jump, the jumper started from a stationary semi-squatted 
position and jumped as high as possible. In the countermovement jump, the subject 
did employ a preliminary downward phase (a countermovement) and so the jump 
involved pre-stretching of muscles. The maximal height reached during the jump 
was measured three times by an electronic contact mat (Newtest, Oulu, Finland), 
and the highest value was used.
5.4  STATISTICAL ANALYSES
All statistical calculations were performed with the SPSS statistical package for 
Windows. When comparing groups, ANOVA or Student´s t-test were used in case 
of normally distributed variables, otherwise the Kruskal-Wallis or Mann-Whitney´s 
tests were used. Continuous variables were correlated with the Pearson´s coeffi cient 
if normally distributed, otherwise the Spearman coeffi cient was used. Dispersion was 
reported as standard deviations (SD) for normally distributed variables, otherwise 
interquartile range (IQR) was given. Multivariate analyses in cross-sectional studies 
were performed by multiple logistic regression when the dependent variable was 
dichotomous and multiple linear regression for continuous dependent variables. 
In longitudinal data, Cox proportional hazard survival regression was used as 
multivariate analysis. 
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6. RESULTS
6.1 STUDY I: PHYSICAL ACTIVITY AND DIABETIC COMPLICA-
TIONS 
6.1.1 DIABETIC NEPHROPATHY
The total amount of leisure-time physical activity in patients with normo- vs. micro- 
vs. macroalbuminuria was (median, IQR) 20.3, 10.5-35.1 vs. 19.9, 9.4-39.7 vs. 18.0, 
7.9-31.7 MET*h/week (overall P=NS). The proportion of patients being sedentary 
was, however, higher in patients with macroalbuminuria compared with normal 
UAER (Figure 3). For patients with ESRD the results were largely dependent upon 
treatment modality and renal function. Patients on dialysis had LTPA 14.5 (2.6-44.3) 
MET*h/week, while those patients who had received a renal transplant and had 
normal renal function (serum creatinine <150 μmol/l) had LTPA 21.9, 14.9-54.9 
MET*h/week (P=NS vs. normoalbuminuria). For renal function estimated with the 
Cockcroft-Gault formula there were no statistically signifi cant differences in total 
LTPA between groups with eGFR ≥90, 60-89, 30-59, and ≤30 ml/min/1.73m2. The 
Pearson´s correlation coeffi cients between LTPA and UAER was -0.03 (P=0.247) 
and LTPA and eGFR was 0.04 (P=0.120). Age- and gender-stratifi cation of the 
association between total LTPA and albuminuria revealed that patients <40 years of 
age and with macroalbuminuria had lower LTPA compared with those with normal 
UAER (Figure 3). Men, but not women, with macroalbuminuria had similarly 
reduced LTPA (fi gure 3). Participation in competitive sports, neither previous nor 
present was associated with albuminuria status. 
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Figure 3.Proportion (%) of sedentary patients (LTPA <10 MET*h/week). *P<0.05 vs. normal UAER.
Despite surprisingly minute differences in total LTPA according to albuminuria 
status and renal function there were, however, differences in the composition 
of LTPA. Intensity was the component of LTPA most clearly associated with 
albuminuria status (Figure 4). Patients with macroalbuminuria, ESRD and 
interestingly also microalbuminuria, performed LTPA of low intensity more 
frequently than patients with normal UAER (30.5 vs. 21.4%, P=0.047 adjusted for 
age and sex for microalbuminuria).  
Figure 4. Proportion (%) of patients with low intensity LTPA.*P<0.05 vs. normal UAER.
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Multiple regression models were performed to adjust for possible confounding 
factors (duration of diabetes, sex, and BMI) for the associations between LTPA and 
diabetic nephropathy. Low frequency (<1 session per week) LTPA (odds ratio, 95% 
CI: 1.88, 1.37-2.57) and low intensity LTPA (2.29, 1.71-3.07), but not total LTPA 
(0.89, 0.77-1.03), were independently associated with diabetic nephropathy. 
6.1.2 DIABETIC RETINOPATHY
Total LTPA for patients without vs. background vs. proliferative retinopathy was 
19.7, 11.0-35.6 vs. 18.9, 9.5-34.3 vs. 19.8, 8.5-35.6 MET*h/week, respectively (overall 
P=NS). Patients with proliferative retinopathy were, however, more frequently 
sedentary than patients without retinopathy (27.9% vs. 21.7%, P<0.01). The 
composition of LTPA was, as for nephropathy, divergent as patients with background 
and those with proliferative retinopathy performed LTPA of low intensity and low 
frequency more commonly than did patients with no retinopathy. Low intensity 
LTPA was independently associated with proliferative retinopathy (1.49, 1.15-1.93) 
in a multiple regression model correcting for duration of diabetes, sex, and BMI.
6.1.3 CVD
Patients with vs. without CVD had total LTPA 18.0, 7.7-36.4 vs. 19.7, 10.2-35.5 
MET*h/week (P=NS). Low intensity LTPA was more common in patients with 
CVD than without (56.4 vs. 24.1%, P<0.01). Frequency of LTPA was not associated 
with prevalence of CVD. Low intensity LTPA was independently associated with 
CVD (2.58, 1.78-3.73) in a multiple regression model correcting for duration of 
diabetes, sex, and BMI.
6.2 STUDY II: PHYSICAL ACTIVITY AND GLYCAEMIC CONTROL
LTPA was associated with HbA
1c
 but this association was, however, found only in 
women (Figure 5). Sedentary patients had higher HbA
1c
 compared with moderately 
active patients. HbA
1c
 was, however, similar in moderately active and active patients. 
The Spearman´s correlation coeffi cients between total LTPA and HbA
1c
 were r=-0.12 
(P=0.007) in women and r=-0.03 (P=NS) in men. Insulin dose (Figure 6) and eGDR 
(Figure 7), an estimate of insulin sensitivity was also inversely associated with LTPA. 
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Figure 5. HbA1c  and physical activity  in patients with type 1 diabetes. Err or bars represent SD:s.
Figure 6. Insulin dose per kg body weight per day and physical activity in patients with type 1 
diabetes. Error bars represent SD:s.
Figure 7. Estimated glucose disposal rate (eGDR)and physical activity in patients with type 1 
diabetes. Values are medians. *P<0.05 vs. active.
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The diabetic complication status of the patients could potentially affect the 
associations between HbA
1c 
and LTPA. A subanalysis was performed only with 
patients free from diabetic complications (UAER <30 mg/24h, no CVD, N=624). 
Hereby, sedentary vs. moderately active vs. active women without complications 
had HbA
1c
 8.7±1.4 vs. 8.2±1.3 vs. 8.2±1.3% (P=0.042), respectively. In men without 
complications corresponding values were 8.3±1.3 vs. 8.1±1.4 vs. 8.1±1.2% (P=0.659), 
respectively. Components of LTPA were also associated with HbA
1c 
(Table 4). There 
were, moreover, gender differences in the components of LTPA. Men more often 
performed high intensity LTPA than women, which in turn performed LTPA with 
higher frequency (Table 4).
Intensity Low Moderate High P-value
Women 8.81.4 (21%) 8.11.2 (66%) 8.41.7 (13%) 0.012
Men 8.10.9 (21%) 8.21.4 (43%) 8.21.5 (36%) 0.724
Frequency <1 time/
week
1-2 times/
week
>2 times/
week
Women 9.01.4 (16%) 8.41.3 (23%) 8.21.3 (61%) 0.008
Men 8.31.0 (26%) 8.31.1 (30%) 8.11.7 (44%) 0.425
Duration <3 h/week 3-6 h/week >6 h/week
Women 8.51.4 (36%) 8.31.4 (31%) 8.11.3 (33%) 0.156
Men 8.31.3 (42%) 8.11.5 (32%) 8.11.2 (26%) 0.173
Table 4. HbA1c by components of LTPA, patients without complications (N=624). Percentage 
values in brackets represent distribution of corresponding level of component of LTPA within each 
gender. P-values were  calculated by ANOVA.
To further explore the impact of confounding factors, a multiple logistic regression 
model was performed correcting for corrected for age, duration of diabetes, social 
class, obesity, blood pressure, serum cholesterol, diabetic nephropathy, CVD, 
and laser-treated retinopathy. Hereby, poor glycaemic control (HbA
1c
 >8.5%) as 
dependent variable. A sedentary level of LTPA (OR, 95% CI: 2.07, 1.18-3-62), insulin 
dose (4.82, 1.31-17.79), and smoking (2.01, 1.11-3.63) were independently associated 
with poor glycaemic control in women with type 1 diabetes. 
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6.3 STUDY III: HBA1C VARIABILITY, RISK OF DIABETIC COMPLI-
CATIONS, AND PHYSICAL ACTIVITY 
Data on HbA
1c
 variability and renal status at follow-up were available for 2107 
patients, and 1845 patients had data on CVD events. The median follow-up time 
was 5.7 years during which 214 patients progressed in renal disease status (to a 
higher albuminuria status or to ESRD) and 158 patients had a CVD event. The 
median number of serial HbA
1c
 measurements per patients was 13. The intrapersonal 
mean of serial HbA
1c
 was 8.5% and SD 0.78. As measures of HbA
1c
 variability, the 
intrapersonal SD (standard deviation) and CV (coeffi cient of variation) were used. 
In Table 5, the mean, SD, and CV of serial HbA
1c
 measurements are given 
according to state of progression in renal disease and CVD events. The intrapersonal 
means of HbA
1c
 were higher in patients that developed microalbuminuria and 
macroalbuminuria, but not ESRD. Furthermore, the intrapersonal HbA
1c
 variability 
was higher in all subgroups of patients that progressed in renal status as both SD 
and CV were higher in the progressors. Patients that suffered a CVD event did not 
differ in mean serial HbA
1c
 from those that did not have a CVD event. The variability 
of HbA
1c
, on the other hand, was higher in those with a CVD event during follow-up.
Mean SD CV Mean SD CV
Renal status
All 8.5 0.76 8.9 9.2 1.01 11.0
Normo -> Micro 8.3 0.74 8.9 9.2 0.94 10.1
Micro -> Macro 8.8 0.77 8.7 9.6 1.08 11.2
Macro -> ESRD 9.0* 0.84 9.2 8.8 1.07 12.0
CVD event 8.5* 0.79 9.1 8.6 0.87 10.0
Table 5. Intrapersonal mean, SD, and CV of serially measured HbA1caccording to progression in 
renal disease and occurrence of a CVD event during follow-up. *P>0.05. All other values P<0.05 
within each group of progression status.
In Figure 8, Kaplan-Meier survival curves for quartiles of SD of serial HbA
1c
 
show a clear association between SD and any progression in renal status. For CVD 
events, the corresponding association was less evident as only the highest quartile 
diverged from the rest. 
  Non-progressors                        Progressors
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Figure 8. Kaplan-Meier survival cures for (A) any progression in renal status and (B) a CVD event 
during follow-up with respect to quartiles of variability (SD) of serially measured HbA1c.
Figure 9 shows Kaplan-Meier survival curves which take both the mean value and 
the variability of serial HbA
1c
 into consideration. As can be expected those patients 
that had low HbA
1c
 with low variability, that is below the population median for 
both mean and SD, had the lowest risk for progression in renal status (fi g. 9A). Both 
high mean and high SD of HbA
1c
 (above the population medians) was accordingly 
associated with the highest risk of any progression in renal status. Patients with high 
mean but low variability of serial HbA
1c
, notably, had the same risk for progression 
in renal status as did patients that had low mean but high variability of HbA
1c
. 
Corresponding analyses for any CVD event showed no separation in Kaplan-Meier 
survival cure analyses (Figure 9B). 
Figure 9. Kaplan-Meier survival cures for (A) any progression in renal status and (B) a CVD event 
during follow-up with respect to mean and variability (SD) of serially measured HbA1c above and 
below the population medians.
The association between the variability of HbA
1c
 and risk of diabetic complications 
could be due to several confounding factors. Therefore, multivariate Cox proportional 
hazard survival regression models were undertaken to adjust for some clinically 
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relevant potential confounders (Table 6). The variability of HbA
1c
 was independently 
associated with progression in renal status and with a CVD event during follow-up 
even when controlling for the mean HbA
1c 
and the number of HbA
1c
 measurements. 
For CVD events, interestingly, the mean of serial HbA
1c
 was not an independent 
predictor of events.
Renal status CVD event
D uration of diabetes (years) 1.01 (0.99-1.02) 1.08 (1.06-1.10)
Male gender 1.74 (1.30-2.33) 1.17 (0.81-1.70)
Systolic blood pressure (mmHg) 1.01 (1.00-1.02) 1.02 (1.01-1.03)
Total cholesterol (mmol/l) 1.19 (1.04-1.36) 1.11 (0.92-1.34)
Ever smoking 1.22 (0.92-1.63) 1.00 (0.70-1.43)
Diabetic nephropathy           - 1.78 (1.20-2.64)
CVD event           - 3.11 (2.10-4.59)
Number of serial  HbA
1c
 measurements 1.09 (0.90-1.31) 0.88 (0.71-1.09)
Intra-personal mean of serial HbA
1c 
(%) 1.34 (1.20-1.51) 1.01 (0.87-1.18)
Intra-personal SD of serial  HbA
1c
1.92 (1.49-2.47) 1.98 (1.39-2.82)
Table 6. Multivariate Cox regression model for any progression in renal status and for any CVD 
event during follow-up. Values are given as HR (95% CI).
To further characterise the associations with the HbA
1c
 variability we investigated 
baseline lifestyle factors in comparison with quartiles of SD of serial HbA
1c
. 
Comparing the lowest with the highest quartile of SD, a higher prevalence of smoking 
(17.5 vs. 33.1%, P<0.01) and low social class (60.7 vs. 76.2%) were found. A sedentary 
level of LTPA was also associated with higher HbA
1c 
variability (Figure 10). 
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Figure 10. Variability (SD) of serial HbA1c compared with the baseline physical activity 
level in (A) all patients (N=775) with data on LTPA and (B) only patients (N=534) with 
normoalbuminuria.*P<0.05 vs. 1st quartile.
In the 775 patients with data on LTPA, the proportion of patients that progressed 
in renal status in sedentary vs. moderately active vs. active patients were 9.2% vs. 
8.1% vs. 5.0% (P=0.127 for trend). Only looking at progression from normo- to 
microalbuminuria, the corresponding proportions were 5.8% vs. 6.7% vs. 3.4% 
(P=0.435). For any CVD event, the proportions were 9.9% vs. 5.2% vs. 5.8% 
(P=0.122), respective. 
6.4. STUDY IV: THE METABOLIC SYNDROME IN TYPE 1 DIABE-
TES AND PHYSICAL ACTIVITY; EFFECT OF THE PPARγ PRO12A-
LA POLYMORPHISM
The NCEP/ATPIII criteria for the metabolic syndrome were fulfi lled in 27.8% of 
the men and in 31.0% of the women. There was no difference in prevalence of 
the metabolic syndrome in subjects with various genotypes of PPARγ Pro12Ala 
polymorphism.
LTPA (median, IQR) in patients with the metabolic syndrome was 17.0, 8.6-31.6 
MET*h/week while being 20.8, 10.8-34.7 MET*h/week in patients not fulfi lling the 
criteria (P=0.038 adj. for age). Figure 11 shows the proportions of patients with the 
metabolic syndrome with respect to total level, intensity, and frequency of LTPA. 
The PPARγ Pro12Ala polymorphism, interestingly, affected the association between 
LTPA and the metabolic syndrome since the association was seen only in carriers 
of the Ala-allele (Figure 11D).
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Figure 11. Prevalence of the metabolic syndrome according to (A) total LTPA, (B) intensity of 
LTPA, and (C) frequency of LTPA. Figure (D) shows total LTPA according to PPARγ Pro12Ala 
genotype. *P<0.05 vs. sedentary or low intensity.
6.5. STUDY V: PHYSICAL FITNESS AND GLYCAEMIC CONTROL 
There were no differences in gender distribution, age, BMI, and smoking between 
patients with type 1 diabetes and nondiabetic controls (Table 7). One patient had 
microalbuminuria, but all were free from clinically evident CVD. 
A B
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Type 1 diabetes Controls
Number of patients 86 27
Gender (% men) 54.7 55.6
Age (years) 28.6±5.2 28.2±6.1
Duration of diabetes (years) 11.5±1.8 -
HbA
1c
 (%) 7.4±0.9 -
BMI (kg/m2) 25.1±3.5 23.8±3.3
Resting systolic BP (mmHg) 124±14 123±14
Resting diastolic BP (mmHg) 75±10 72±11
Resting heart rate (bpm) 70±11 66±15
Antihypertensive medication (%) 9.4 0
Current smoker (%) 17.4 22.2
Physical activity (MET*h/week) 17.2 (11.1-26.0) 28.8 (22.3-45.6)*
 
Table 7. Clinical characteristics for patients with type 1 diabetes and nondiabetic controls.*P<0.05 
vs. patients with diabetes. Values are given as N, mean±SD, median (IQR), or %. 
V O
2max 
was lower in patients with type 1 diabetes compared with controls (Figure 
11). Ten patients, all with diabetes, terminated the exercise test prematurely but 
exclusion of these patients did not have a major impact on the association. Both 
the respiratory compensation point (RCP) and the anaerobic threshold (AT) were 
additionally lower in patients with diabetes compared with controls. Women with 
diabetes had especially low indicators of aerobic fi tness as the AT
 
was at a level below 
the oxygen consumption corresponding to brisk walking (Figure 12, dotted line).
 
Figure 12. White bar: fatigue (V O2max). Grey bar: respiratory compensation point. Black bar: 
anaerobic threshold. Error bars: standard deviations. Dotted horizontal line:  the oxygen 
consumption (18 ml/kg/min) corresponding to brisk walking. *P<0.05 vs. controls within the same 
gender. 
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Handgrip strength was similar in patients with diabetes and in controls. Lower 
extremity strength output was, however, lower in women with diabetes vs. controls 
due to lower height of both the squat jump (19±4 vs. 24±4 cm, P=0.001) and of 
the countermovement jump (21±5 vs. 25±5 cm, P=0.008). Lower limb strength 
was similar in men with diabetes and controls. 
HbA
1c
 correlated negatively with V O
2max 
in men, but not in women, with diabetes 
(Figure 13). In women, the dominant hand grip strength showed a negative 
correlation with HbA
1c
 (Table 8), while lower limb strength correlated with HbA
1c
 
in men. 
Figure 13. Scatterplot of HbA1c and V O2max in (A) men and (B) women with type 1 diabetes.
Men Women
V O
2max
-0.50** -0.06
Height of squat jump -0.33*  0.10
Height of countermovement jump -0.36* -0.06
Dominant hand grip strength -0.28 -0.02
Non-dominant hand grip strength -0.26 -0.41*
Table 8. Correlation coeffi cients between HbA1c and measures of aerobic and strength fi tness in 
patients with type 1 diabetes.*P<0.05.**P<0.01.
To control for potential confounding variables for the association between HbA
1c
 
and V O
2max
, we performed a multiple linear regression model. HbA
1c
 was chosen 
as the dependent variable, while the pre-test blood glucose concentration, age, 
BMI, and V O
2max
 were independent variables. In men, but not in women, V O
2max
 
(standardized coeffi cient β=-0.64, P<0.001) was independently associated with 
HbA
1c
.
A B
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7. DISCUSSION
7.1 STUDY DESIGN, PATIENTS, AND METHODS
Studies I-V include patients from the nationwide FinnDiane Study while the patients 
of study V were part of the IDEAL study which  constitute a subpopulation of 
FinnDiane patients with short duration of type 1 diabetes that are more extensively 
studied in search of early markers for diabetic complications. The FinnDiane study 
recruits patients at all levels of the Finnish health care system; from primary health 
care up to university central hospitals. The patients are recruited simply based 
on a diagnosis of type 1 diabetes with no prerequisites regarding their diabetic 
complications. Due to the ongoing nature of the FinnDiane Study, the studies I-IV 
have somewhat differing sets of patients. The physical activity questionnaire was 
not in use at time of the launch of the study and therefore the number of patients 
with data on LTPA is lower than the total amount of patients. Some patients have 
additionally chosen not to return the questionnaire due to reasons that are not 
assessed in the study. Such reasons may include that the questionnaire is rendered 
laborious and time-consuming. Physically active patients may also be more likely 
than sedentary patients to complete the questionnaire. Four studies in this thesis 
have a cross-sectional study design which introduces diffi culties to discern causal 
relationships. One study, however, had a longitudinal study design which takes 
advantage of data from two study occasions of each patient. FinnDiane is a 
multicenter study, thus with numerous researchers collecting clinical data. The 
use of standardised forms and questionnaires, as well as a written manual to ensure 
similar methods of measurement of clinical characteristics, decrease the possible 
heterogeneity caused by differences between researchers.           
7.2 STUDY I
In our cross-sectional analysis, patients with diabetic micro- and macrovascular 
complications reported different patterns of LTPA compared with patients without 
complications. Patients with diabetic nephropathy and proliferative retinopathy, 
compared with patients without complications, more frequently reported a level of 
LTPA that did not meet the general physical activity recommendations. Concerning 
components of LTPA, low frequency was associated with diabetic nephropathy. 
However, the most prominent difference between patients with various degrees of 
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complications was the intensity of LTPA, since low intensity was associated with 
impaired renal function, and with increasing degree of proteinuria, retinopathy, 
and CVD. 
The patient’s ability to exercise may be reduced by diabetic complications. 
Macrovascular disease is an evident limitation due to exercise-induced myocardial 
ischaemia, systolic or diastolic cardiac dysfunction, or ischaemia in the lower limbs. 
Patients with CVD are frequently treated with β-adrenergic receptor blockers, which 
may cause exercise intolerance. Diabetic nephropathy is strongly associated with 
CVD 6, and patients with nephropathy have a 37-fold increased risk for an early 
death due to CVD 7. A reduction in renal function, especially in diabetic nephropathy 
151, is associated with a decrease in the blood haemoglobin concentration due to an 
impaired renal production of erythropoietin, and this “renal anaemia” may interfere 
with oxygen delivery during exercise. Autonomic neuropathy is a microvascular 
diabetic complication which shows considerable co-morbidity with other diabetic 
complications 301. Autonomic neuropathy is commonly associated with exercise 
intolerance presumably due to inadequate responses in heart rate and blood 
pressure during exercise 302. Particular attention should be paid to cardiac autonomic 
neuropathy, which is a risk factor for silent myocardial ischaemia and sudden 
death. An impaired awareness of hypoglycaemia has been attributed to autonomic 
neuropathy 303 which may increase the risk of exercise-induced hypoglycaemia. 
Peripheral neuropathy is also likely to impair physical activity due to a loss of 
sensation in the feet. Diabetic foot ulcers, which may develop from impaired 
peripheral arterial circulation or sensory neuropathy, or often from both factors 
acting in concert, may likewise lead to a decreased physical activity. Both diabetes 
and the diabetic complications are associated with endothelial dysfunction 304, 305, 
which could lead to impairment of vasodilation in exercising skeletal muscle tissue, 
possibly through reduced nitric oxide sensitivity. Finally, an increased prevalence 
of depression has been associated with diabetic complications 306, and which may 
lead to a decrease in physical activity. 
The differences in LTPA habits according to the diabetic complication status 
are probably largely attributable to abovementioned exercise-limiting factors. 
However, the difference in patients with microalbuminuria compared with patients 
with normal UAER (lower intensity and a trend towards more sedentary patients 
in the former group) is an interesting fi nding. Microalbuminuria in patients with 
type 1 diabetes would probably not cause exercise intolerance because patients 
with microalbuminuria usually do not have decreased renal function. Therefore, 
low LTPA might precede the development of microalbuminuria, even though there 
are indications that patients with microalbuminuria might have a reduced exercise 
capacity compared with normoalbuminuric patients 261.
Possible mechanisms by which physical activity may prevent the development 
of diabetic complications are lowering of blood pressure and improvement of lipid 
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profi le, glycaemic control, insulin sensitivity, and endothelial function. Especially an 
effect through insulin sensitivity is appealing, since insulin resistance is thought to play 
a role in the development of diabetic complications 307, including microalbuminuria 
123. Physical activity has further been shown to have anti-infl ammatory effects 308, 
and chronic low-grade infl ammation has been implicated in the pathogenesis of 
diabetic complications 309. Finally, increased UAER has been proposed as a sign of 
global vascular dysfunction in patients with type 1 diabetes according to the Steno 
hypothesis 183, and regular exercise training has been shown to improve endothelial 
function in patients with type 1 273 and type 2 diabetes 310. 
Regarding the clinical implications of the study, a limitation is the cross-
sectional study design. A longitudinal study design would have provided evidence 
for the role of physical activity in the development and progression rate of diabetic 
complications. To our best knowledge, however, there are no prospective studies 
available addressing this issue, not even involving patients with type 2 diabetes. Moy 
et al 272 showed in a seven-year follow-up study of patients with type 1 diabetes that a 
higher baseline physical activity level was predictive of lower mortality independently 
of diabetic complications at baseline, but unfortunately complication status at follow-
up was not assessed. Prospective epidemiological studies and randomized controlled 
trials are needed to provide further evidence for the role of physical activity in the 
prevention of diabetic complications in patients with type 1 diabetes. 
7.3 STUDY II
The main fi nding of this cross-sectional study was that for women with type 1 
diabetes, physical activity was associated with glycaemic control. A sedentary 
level of LTPA, defi ned as below the general physical activity recommendations, 
was associated with higher HbA
1c
 compared with female patients that meet the 
recommendations. High levels of LTPA, on the other hand, was associated with 
similar glycaemic control as did moderate levels of LTPA, which suggests a non-
linear relationship between LTPA and HbA
1c
. The linear relationship between HbA
1c
 
and LTPA was low, and a correlation coeffi cient of -0.12 for women indicates that 
LTPA would explain only 1.4% of the total variance in HbA
1c
 in these patients. A mean 
HbA
1c 
difference of 0.5%-units between sedentary and non-sedentary patients can, 
however, be considered clinically relevant. A similar association between LTPA and 
HbA
1c
 was evident also for patients free from diabetic complications, which indicates 
an effect independent of patients being sedentary simply due to a high disease 
burden which in itself associated with poor glycaemic control. Other confounders 
such as age, obesity, smoking, and social class did not explain the association either. 
It should be noted, though, that we found no association between LTPA and HbA
1c
 
in men with type 1 diabetes. 
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Physical activity may improve the glycaemic control of patients with type 1 
diabetes, and a plausible mechanism is through improved insulin sensitivity 11-13. 
The effect on glycaemic control seems, however, to be smaller in patients with type 1 
compared with type 2 diabetes. Most physical activity intervention studies in type 1 
diabetes have failed to show any effect on glycaemic control (see section 2.4.2.1). In 
type 2 diabetes, on the other hand, there is evidence showing a reduction in HbA
1c 
by physical activity intervention, and a meta-analysis showed a mean reduction 
in HbA
1c
 by 0.66%-units 10. The reason behind these divergent fi ndings in type 1 
and type 2 diabetes has not been adequately addressed.  A potential positive effect 
of physical activity on glycaemic control in type 1 diabetes can be thought to be 
reduced by hypoglycaemia during, or more frequently after, a bout of physical 
activity. Patients with type 2 diabetes are not prone to hypoglycaemia to the same 
extent as in type 1 diabetes. Exercise-induced hypoglycaemia, or even just a fear 
thereof, may cause patients with type 1 diabetes to take behavioural actions to keep 
the blood glucose concentrations before, during and/or after physical activity at a 
higher level than normal by reducing the insulin doses and by excess carbohydrate 
loading. Such behaviour may be thought to abolish a positive effect of physical 
activity on glycaemic control. Our data cannot, however, address this issue since 
we lacked data on dietary factors. Insulin doses were lower in patients that were 
more physically active but whether this is due to increased insulin sensitivity or due 
to reduction in insulin doses due to fear of hypoglycaemia is unclear. 
The reason behind the lack of association between LTPA and HbA
1c
 in men with 
type 1 diabetes cannot be fully determined in our study. Men tended, as compared 
with women, to report LTPA of higher intensity while women reported higher 
frequency and longer duration of their physical activity sessions. The higher the 
intensity, the higher is also usually the activation of the counteractive hormonal 
responses to insulin (most importantly adrenalin, glucagon, and cortisol) with 
subsequent increase in blood glucose concentrations. This response, on the other 
hand, may also be of benefi t since a short bout of high intensity activity, for instance 
the 10 s maximal sprint240, may decrease the risk of post-exercise hypoglycaemia. 
Longer sessions of high intensity physical activity might, however, cause a different 
hormonal response than a 10 s maximal sprint.
Our data regarding LTPA and glycaemic control is based on an observational 
study and we therefore cannot draw conclusions about the causality and about the 
isolated effect of physical activity independently of other lifestyle factors. There is 
usually signifi cant association between different lifestyle factors such as physical 
activity, diet, smoking, alcohol use, and other behaviour affecting health outcomes 
such as diabetes treatment compliance. It is possible that the physical activity is a 
marker of a generally healthy lifestyle that in turn translates into a more benefi cial 
glycaemic control. 
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7.4 STUDY III
We demonstrated an association between the variability of HbA
1c 
and the risk of 
progression in renal status and a CVD event during follow-up. We found that a 
higher variability, defi ned as the SD of serially measured HbA
1c
, was associated 
with higher incidences of both renal and cardiovascular disease progression. The 
mean HbA
1c 
was important also for progression in renal disease, which has been 
shown previously in several intervention studies 110-112 including the landmark study 
the DCCT 103. The fi ndings regarding HbA
1c 
variability and progression of renal 
disease are in accordance with recent data from the DCCT 121. Our data on HbA
1c
 
variability differ from the data from the DCCT in the sense that the FinnDiane is 
a purely observational, non-interventional study whereas the DCCT was by design 
an intervention aimed at reducing the HbA
1c
 of the participants in the intensive 
treatment arm. Thus there is a possibility of iatrogenic HbA
1c
 variability due to 
treatment intervention in the DCCT, even though this risk was somewhat reduced 
by exclusion of HbA
1c
 measurements from the fi rst 6 months of intervention, and 
also that an association was seen also in the conventionally treated arm. 
Our serial HbA
1c
 data were gathered from the local study centres and this may 
introduce two potential problems. First, the measurements were accordingly not 
performed in a central laboratory. The HbA
1c
 variability, however, was calculated 
on the intrapersonal level which means that the great majority of the HbA
1c
 
measurements from which the variability was derived in fact were measured in 
the same laboratory at each local study centre. Moreover, the concerns were also 
relieved by the fact that the HbA
1c
 assays in Finland has been shown to have low 
coeffi cient of variation and a high correlation with the DCCT reference method311. 
Second, due to the observational study design, the intervals between the HbA
1c
 
measurements were not pre-specifi ed and thus dependent on the clinical follow-up 
setting of each patient. The number of HbA
1c
 measurements could have affected 
the variability, but this was statistically corrected for. Another potential statistical 
source of error was that higher mean HbA
1c
 in the patients that progressed in 
renal or cardiovascular status lead to higher absolute SD values and therefore the 
variability of HbA
1c 
might appear greater, but this was adjusted for by the use of 
the coeffi cient of variation for HbA
1c
 and by multivariate Cox regression analyses. 
Our study included prospective data on CVD events, which were not reported by 
the DCCT 121. Our main fi nding was that the variability, but not the mean, of serial 
HbA
1c
 was predictive of a CVD event during follow-up. Previous data regarding the 
level of HbA
1c
 and risk of CVD in patients with type 1 diabetes are contradictive 312-
319. In type 2 diabetes, the effect of lowering HbA
1c
 on CVD risk has recently been 
debated 196 due to failure to show any benefi t in large randomised clinical trials. 
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Glycaemic variability in patients with type 1 diabetes has previously been studied 
in the form of short-term glycaemic excursions and their effect on outcomes relevant 
to risk of diabetic complications. It has been shown that glucose variability measured 
by continuous glucose measurement systems (CGMS) is associated with markers 
of oxidative stress in patients with type 2 320 but not type 1 321 diabetes. The CGMS 
measurements are mostly performed in small patient materials and therefore 
large-scale epidemiological analyses have employed other measures of glycaemic 
variability. In the DCCT, the variability of intrapersonal, within-day measured 
blood glucose concentrations were not predictive of either diabetic nephropathy 
or retinopathy 119.
The HbA
1c
 variability and the abovementioned short-term glycaemic variability 
are probably two different entities with differing underlying mechanisms. It is 
possible that the HbA
1c
 variability is affected by behavioural factors since the 
HbA
1c
 variability associated with physical activity, smoking, and social class. The 
fi nding that low physical activity (<10 MET*h/week) was associated with increased 
variability of HbA
1c
 was somewhat unexpected. This association was also evident 
exclusively in patients with normoalbuminuria at baseline which indicates that the 
association was not due to underlying diabetic complications causing both reduced 
physical activity (as shown in Study I) and increased HbA
1c
 variability. 
The mechanisms behind the association between HbA
1c
 variability and the 
increased risk of diabetic complications are unclear. The possibility of a secondary 
effect to variation in insulin sensitivity may imply an involvement of infections, and 
this speculation was reinforced by recent data from the FinnDiane Study showing an 
association between serum lipopolysaccharide activity, which is a marker of gram-
negative bacterial infections, and increased risk of progression in renal disease in 
patients with type 1 diabetes 322.  
7.5 STUDY IV
Low leisure-time physical activity showed an association with higher prevalence 
of the metabolic syndrome in patients with type 1 diabetes. This is in accordance 
with other studies showing an inverse relationship between physical activity and the 
prevalence of the metabolic syndrome in nondiabetic and type 2 diabetic patients 
323, 324. In this study, the PPARγ Pro12Ala polymorphism was not associated with 
the metabolic syndrome. We found, however, a PPARγ genotype-dependent 
association between the metabolic syndrome and LTPA, since the association was 
only observed in Ala-carriers. In patients with the Ala allele, the prevalence of the 
metabolic syndrome was 2.4-fold higher in sedentary compared with physically 
active patients, while patients with the Pro12Pro genotype showed no difference 
in prevalence of the metabolic syndrome according to level of LTPA. 
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Carriers of the Ala-allele have been shown to have reduced PPARγ receptor 
activity compared to subjects with the Pro12Pro genotype 325. There is data supporting 
that Ala-carriers have a lower risk of developing type 2 diabetes than subjects with 
the Pro12Pro genotype 326. However, it should be noticed that confl icting studies have 
also been published where the Ala-allele has been associated with increased risk of 
type 2 diabetes 327-329 and with higher prevalence of obesity 330, 331. Such a variation 
in risk magnitude may refl ect the presence of environmental factors modifying the 
association, for instance physical activity.
Interestingly, it has been shown that the Pro12Ala polymorphism of the PPARγ 
gene may modulate exercise-induced responses in insulin sensitivity and glucose 
homeostasis. In a Japanese study, 123 men with normal glucose tolerance were 
genotyped for PPARγ and participated in a 3-month exercise intervention 286. 
Patients with the Pro12Ala genotype gained a greater reduction in fasting insulin level 
and HOMA index compared to patients with Pro12Pro genotype, with no signifi cant 
difference in weight reduction. Similarly, Weiss et al reported that after a 6-month 
exercise intervention, a 4-fold greater decrease both in fasting insulin and insulin 
AUC (in an oral glucose tolerance test) was seen in healthy males with the Pro12Ala 
genotype compared to Pro12Pro, however no difference was seen in females 287. In 
addition, data on type 2 diabetic patients suggest that the Pro12Ala polymorphism 
infl uences the glycaemic response to exercise; Ala-carriers had a greater reduction in 
fasting plasma glucose, though not in HbA
1c
, independent of weight reduction after 
a 3-month exercise intervention of 139 previously sedentary type 2 diabetic patients 
288. In the Finnish Diabetes Prevention Study (DPS), 522 subjects with impaired 
glucose tolerance were randomized to either an exercise and diet intervention or 
a control group; 490 of these subjects were genotyped for PPARγ Pro12Ala 329. In 
the intervention group, subjects homozygous for the Ala-allele lost more weight 
than subjects with Pro12Pro genotype. During follow-up, none of the subjects with 
Ala12Ala genotype in the intervention group developed type 2 diabetes even though 
the Ala-allele was associated with a 2.11-fold increase in risk for developing diabetes 
in the whole study population (intervention and control subjects combined). It 
was further shown that the there is a gene-environment interaction between the 
PPARγ Pro12Ala polymorphism and physical activity on the risk of developing 
type 2 diabetes in the DPS 332. It has previously been shown that physiological and 
biochemical responses to physical activity have a hereditary component 283, and an 
annual review on the genetics of exercise responses is published 289. The PPARγ 
Pro12Ala polymorphism, or another gene variant being in linkage disequilibrium, 
might be, based on both present and previous studies, involved in exercise-induced 
responses in insulin and glucose homeostasis. 
In this study, waist circumference seemed to have a major impact both on the 
association between LTPA and metabolic syndrome and on the PPARγ genotype-
dependent association between metabolic syndrome and LTPA. This speaks in 
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favour of a pivotal role of insulin sensitivity since central obesity is tightly linked 
to decreased insulin sensitivity. Insulin resistance is considered to be the key feature 
of the metabolic syndrome 201. We previously showed that LTPA is associated with 
insulin sensitivity in type 1 diabetic patients (Study II). The overall prevalence of 
the metabolic syndrome in this study was lower (29.5%) than previously reported 
(39%) 27, presumably due to exclusion of patients with end-stage renal disease and/
or a previous cardiovascular event. 
This study has some limitations, most of which are attributable to the cross-
sectional study design. The association between LTPA and the metabolic syndrome 
could have been caused by exercise-limiting factors themselves associated with the 
metabolic syndrome (for instance diabetic nephropathy). However, patients with 
end-stage renal disease or a previous cardiovascular event were excluded from the 
analyses, which reduce the risk for complication-derived physical activity bias. We 
found no association between the PPARγ Pro12Ala polymorphism and the metabolic 
syndrome, but we cannot exclude a type 2 statistical error due to an insuffi cient 
number of patients. The differences in association between LTPA and the metabolic 
syndrome according to subgroup analyses of PPARγ genotype cannot be explained 
by loss of statistical power in the Pro12Pro group because the number of patients 
was larger than in the group of Ala-carriers where the association was apparent. 
In conclusion, physical activity might reduce the risk that type 1 diabetic patients 
develop the metabolic syndrome, a feature shared with the metabolic syndrome in 
nondiabetic and type 2 diabetic subjects. The common Pro12Ala polymorphism of 
the PPARγ gene does not seem to be related to the metabolic syndrome in type 1 
diabetic patients. However, carriers of the Ala allele might especially benefi t from 
being physically active. 
7.6. STUDY V
Young adults with type 1 diabetes have reduced aerobic work capacity compared 
with nondiabetic controls of the same age. Not only the maximal capacity (V O
2max
), 
but also the RCP and AT were similarly decreased in patients with type 1 diabetes 
which indicates an overall lower aerobic fi tness level.  Previous studies of the fi tness 
level of patient with type 1 diabetes have indicated reduced 274, 275 or normal 276, 
277  aerobic fi tness compared with controls. The IDEAL Study recruited patients 
with a population-based approach, which in contrast to earlier works means that 
the results may be more easily generalised. These results were especially clear in 
women, and the aerobic fi tness level of the young women with type 1 diabetes 
tested in our study was surprisingly low. The fi nding that the AT in women with 
diabetes was at a level below that of brisk walking further strengthens this concern. 
The differences in strength fi tness were not as pronounced as those of aerobic 
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fi tness but differences were still observed. Strength fi tness has not previously to 
our knowledge been compared in patients with diabetes and in nondiabetic peers. 
HbA
1c
 correlated inversely with V O
2max 
in men with diabetes, but not in women. 
The distribution of V O
2max 
in women was considerably narrower in women than in 
men which may have decreased the statistical power to detect a true association 
also in women. There is some previous data showing a similar inverse association 
between measures of aerobic fi tness and HbA
1c
 in patients with type 1 diabetes 276, 281. 
A more recent study of consecutive patients at a diabetes outpatient clinic, however, 
showed that a higher aerobic fi tness was associated with higher HbA
1c
, but the fi tness 
was measured with an indirect method and not by pulmonary gas exchange 282. 
That study also showed an association between higher strength fi tness and higher 
HbA
1c
, but our study showed the opposite association because lower limb strength 
in men and upper limb strength in women were inversely associated with HbA
1c
. 
The reason(s) for a lower fi tness level in young adult Finnish patients with type 
1 diabetes compared with nondiabetic controls was not evident from our study. The 
physical activity of patients with diabetes was lower, which certainly explain part 
of the fi ndings. The difference in physical activity was less clear in women with 
and without diabetes, and as the largest differences in fi tness level were found 
in women, there are probably also other factors involved. It has been shown that 
elevated UAER is associated with reduced aerobic work capacity in patients with 
type 1 diabetes 261, but only one patient in our study had microalbuminuria and 
we found no correlation between UAER and V O
2max
.
 
Chronic hyperglycaemia can, 
however, cause disturbances of the microcirculation of the muscles 279 and of the 
lungs 278, with plausible implications for the maximal work capacity of patients with 
diabetes. Recent data from the IDEAL Study showed signs of impaired autonomic 
nervous system responses, especially a reduced barorefl ex sensitivity, which may 
cause abnormal responses in heart rate and blood pressure during physical activity 
333. 
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8. SUMMARY AND CONCLUSIONS
I The physical activity of patients with diabetic complications was reduced 
when compared with patients without microvascular and macrovascular 
diabetic complications. This study had a cross-sectional design, and therefore 
the causal relationships cannot be fully determined. Patients with severe 
disease such as diabetic nephropathy (especially ESRD) and CVD have 
a reduced exercise tolerance and capability and therefore the lower level 
of physical activity is probably to a large extent secondary to these severe 
complications. Patients with microalbuminuria, on the other hand, also 
showed a different physical activity pattern as compared with patients with 
normal UAER, and in this case it is possible that the physical activity may 
precede the development of microalbuminuria. Future prospective studies 
will address the question whether a physically active lifestyle can reduce the 
incidence of diabetic complications in type 1 diabetes. 
II  Low physical activity was associated with poor glycaemic control in patients 
with type diabetes, and this association was evident in women. A high level 
of physical activity was associated with a similar glycaemic control as a 
moderate level of physical activity. A sedentary level was defi ned as physical 
activity below the general recommendations for regular physical activity. The 
association between the glycaemic control and physical activity was seen also 
in patients with no signs of diabetic complications, indicating that the results 
were not entirely due to the diabetic complication status. Insulin sensitivity 
was also better in patients with higher physical activity level. The results 
may indicate that avoidance of a sedentary lifestyle may facilitate a more 
benefi cial long-term blood glucose control in type 1 diabetes.
III In a prospective setting, a higher variability of HbA
1c
 was associated with 
higher risk for progression in renal disease and with CVD events in patients 
with type 1 diabetes. For CVD events, the HbA
1c
 variability was predictive 
even though the mean level of HbA
1c
 was not. A sedentary level of physical 
activity was associated with higher HbA
1c
 variability. The underlying meaning 
of having a high HbA
1c
 variability is so far unclear and needs to be further 
characterised. There was a trend towards patients with low physical activity 
at baseline to have higher incidence of progression in renal disease and CVD 
events, even though the results did not reach statistical signifi cance.
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IV The metabolic syndrome in patients with type 1 diabetes has recently been 
described using standard defi nitions. A higher level of physical activity was 
associated with a lower prevalence of the metabolic syndrome in patients with 
type 1 diabetes. We further showed that the PPARγ Pro12Ala polymorphism 
— a well-known gene variant for the risk of obesity, insulin resistance, and 
type 2 diabetes — was not associated with the metabolic syndrome in type 1 
diabetes; however we cannot fully exclude a type 2 statistical error due to a 
lack of power. The PPARγ Pro12Ala polymorphism affected the association 
between physical activity and the prevalence of the metabolic syndrome 
because the association was evident only in carriers of the Ala-allele. 
V We showed in a population-based cohort of young adults with type 1 diabetes 
of short duration that the aerobic work capacity is reduced compared with 
nondiabetic controls of similar age. The golden standard of measurement 
of aerobic fi tness, direct measurement of the alveolar ventilation, was used. 
Women with type 1 diabetes had an alarmingly low level of aerobic physical 
fi tness. The strength fi tness was also somewhat reduced in patients with type 
1 diabetes. In men, a higher level of aerobic fi tness was associated with lower 
HbA
1c
 and V O
2max 
explained 25% of the variance in HbA
1c
. In women, upper 
limb strength, but not aerobic fi tness, was inversely associated with HbA
1c
. 
The underlying reasons for a decreased physical fi tness in patients with type 
1 diabetes warrants further studies.
General conclusions: This thesis shows that patients with type 1 diabetes should 
be encouraged to be physically active because an active lifestyle is associated with a 
more benefi cial glycaemic profi le that can translate into a decreased risk for diabetic 
complication.
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